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Background: The Test-Treatment Pathway has been proposed as a
method to link test accuracy to downstream outcomes. By
describing the clinical actions before and after testing, it illus-
trates how a test is positioned in the pathway, relative to other
tests and diagnostics, and how the introduction of a new test
may change the current diagnostics pathway. However, there is
limited practical guidance on how to model such Test-Treatment
Pathways.
Methods: We selected the Patient - Index test- Comparator - Out-
come (PICO) format, as also used elsewhere in evidence-based
medicine, as a starting point for building the Test-Treatment
Pathways. From there we developed a structured set of triggering
questions. We defined these questions based on several brainstorm
sessions and iteratively made changes to this basic structure after
three rounds of user testing. During the user testing meetings, a
pathway was drawn for each specific application. All sessions were
recorded both on audio and video.
Results: We present examples of four different Test-Treatment
Pathways. User testing revealed that all users found the process of
drawing the pathway very useful, but they also felt that this is just
the first step in a process. The steps from pathway derivation to
key questions remains difficult. Challenges in deriving the pathway
were that interviewee(s) may wander off topic and that some prob-
lems cannot be captured in only one pathway. Further training was
deemed desirable. Users would also like to see an electronic tool.
They had no clear preference when offered a choice between a
more open interviewing approach versus a more closed checklist
approach.
Discussion: Modelling Test-Treatment pathways is a useful step in
synthesizing the evidence about medical tests and developing
recommendations about them, but further technical development
and training are needed to facilitate their use in evidence-based
medicine.
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Identifying studies of diagnostic test accuracy (DTA) is challenging.
Poor reporting and inconsistent indexing hampers retrieval, and the
lack of validated filters means that sensitive searches often yield tens
of thousands of results which require further manual assessment.
Machine learning (ML) and crowdsourcing have shown to be highly
effective at identifying reports of randomized trials, with Cochrane’s
Embase screening project accurately identifying over 20,000 reports
using a crowd model. Additionally, the project generated a large data
set that could be used to train ML systems. The new workflow for
RCT identification will combine automated and human screening to
optimize system efficiency.
Aims and objectives
This study set out to evaluate the application of these two innovative
approaches to DTA identification.
Methods
A gold standard data set (n = 1120) was created, composed of known
DTA studies and realistic non-DTA reports. This data set was made
available to both machine and crowd. Two ML strategies were
evaluated: 1. An ‘active learning’ simulation, in which the abstracts
presented for manual assessment were prioritized as a function of
their predicted probability of relevance; 2. A binary classifier, which was
evaluated via cross-validation. Outcomes of interest were machine and
crowd recall and precision.
Results
At the time of writing, the experiments are ongoing. The active learning
approach achieved 95% recall at a cost of 30% being manually
screened, increasing to 100% after 77% screened. The binary classifier
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retrieved DTA articles with 95% recall, and 40% precision; 100% recall
was possible, but with an associated precision of 13%.
Discussion
The gold standard used for this study was small but had the advantage
of not being generated through the relative recall method. If the crowd
can do this successfully, as has been shown in the case of Cochrane’s
Embase project, then we will be in a position to create a vast
human-generated gold standard dataset (across all relevant health-
care areas) that can be used to further improve machine learning
accuracy.
This work could also be used to inform methodological filter devel-
opment and refinement.
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A plain language summary (PLS) is a stand-alone summary of a
Cochrane systematic review and should provide rapid access to
its content. A clear PLS is essential to ensure that systematic re-
views are useful to users who are not familiar with the more
technical content of the review. Explaining the results of a Diag-
nostic Test Accuracy (DTA) review in plain language is challen-
ging. The review methodology and results are less familiar than
reviews of interventions and the two dimensional nature of the
measure of a test’s accuracy (sensitivity and specificity) introduces
further complexity. Additionally, DTA reviews are characterized by
a large degree of heterogeneity in results across studies. The rea-
son for this variation is not always clear and explaining this to
readers, especially lay readers, is difficult. A further challenge is
providing information about the downstream consequences of
testing. Challenges in the interpretation of DTA reviews may be
different for different target user groups, but this is something
that has yet to be established. Ideally, a PLS should be accessible
to all potential target audiences (patients, clinicians, policy
makers).
The overall aim of this project is to develop a template and guid-
ance for PLS for Cochrane DTA reviews. We are using a four
staged approach to develop this: qualitative focus groups, one-
on-one user testing, web-based survey, and producing a template
and guidance for PLS for DTA reviews based on the findings
from the first three stages (Fig. 1). This presentation will provide
a summary of the results from the focus groups, user testing and
first rounds of the web-based survey. We will present the current
version of the proposed PLS based on an example review of the
IQCODE for diagnosing dementia. We will then invite the audi-
ence to provide feedback on various aspects of the proposed
example PLS using interactive turning point voting software.
Feedback from the presentation will then be incorporated into
the next version of the PLS.
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Background: Quality assessment of included studies is a crucial step in
any systematic review. Review and synthesis of prediction modelling
studies is a relatively new and evolving area and a tool facilitating
quality assessment for prognostic and diagnostic prediction modelling
studies is needed.
Objectives: To introduce PROBAST, a tool for assessing the risk of
bias and applicability of prediction modelling studies.
Methods: A Delphi process, involving 42 experts in the field of
prediction research, was used until agreement on the content of the
final tool. Existing initiatives in the field of prediction research such as
the REMARK (Reporting Recommendations for Tumor Marker Prognostic
Studies) guidelines and the TRIPOD prediction model reporting guide-
lines formed part of the evidence base for the tool development. The
scope of PROBAST was determined with consideration of existing tools,
such as QUIPS and QUADAS.
Results: After seven rounds of the Delphi procedure, a final tool has
been developed which utilises a domain-based structure supported
by signalling questions similar to QUADAS-2, which assesses risk of
bias and applicability of diagnostic accuracy studies. PROBAST as-
sesses the risk of bias and applicability of prediction modelling
Fig. 1 (abstract O3). See text for description
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studies. Risk of bias refers to the likelihood that a prediction model
leads to distorted predictive performance for its intended use and tar-
geted individuals. The predictive performance is typically evaluated
using calibration, discrimination, and (re)classification. Applicability
refers to the extent to which the prediction model from the primary
study matches your systematic review question, for example in terms
of the population or outcomes of interest.
PROBAST comprises five domains (participant selection, outcome, pre-
dictors, sample size and flow, and analysis) and 24 signalling questions
grouped within these domains.
Conclusions: PROBAST can be used for the quality assessment of pre-
diction modelling studies. The presentation will give an overview of the
development process and the final version of the tool (including the
addressed domains and signalling questions).
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Background
Summarizing the information of many studies using a meta-
analysis becomes more and more important, also in the field of
diagnostic studies. The special challenge in meta-analysis of diag-
nostic accuracy studies is that in general sensitivity and specificity
are co-primary endpoints. Across the studies, both endpoints are
correlated, and this correlation has to be considered in the
analysis.
Methods
The standard approach for such a meta-analysis is the bivariate
logistic random effects model. An alternative, more flexible ap-
proach is to use marginal beta-binomial distributions for the true
positives and the true negatives, linked by copula distributions.
However, both approaches can lead to convergence problems.
We developed a new, nonparametric approach of analysis, which
has greater flexibility with respect to the correlation structure.
Furthermore, the nonparametric approach avoids convergence
problems.
Results
In a simulation study, it became apparent that the empirical cover-
age of all three approaches is in general below the nominal level. Re-
garding bias, empirical coverage, and mean squared error the
nonparametric model is often superior to the standard model, and
comparable with the copula model. I will also show the application
of the three approaches for two example meta-analyses: one with
very high specificities and low variability, and one with an outlier
study.
Conclusion
In summary, the nonparametric model as compared with the stand-
ard model and the copula model has better or comparable statistical
properties, no restrictions on the correlations structure and always
converges. Subject of further research is the consideration of mul-
tiple thresholds per study.
Reference
[1] Zapf A, Hoyer A, Kramer K, Kuss O (2015). Nonparametric meta‐analysis
for diagnostic accuracy studies. Statistics in Medicine, 34(29):3831–41.
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Introduction: For continuous tests, primary studies usually report test
accuracy results at multiple thresholds, but the set of thresholds used
often differs. This creates missing data when performing a meta-
analysis at each threshold. A standard meta-analysis (NI: No Imput-
ation) ignores such missing data. A Single Imputation (SI) approach
was recently proposed to recover missing threshold results using a
simple piecewise linear interpolation. Here, we propose a new
method (MIDC) that performs Multiple Imputation of the missing
threshold results using Discrete Combinations, and compare the ap-
proaches via simulation.
Methods: The new MIDC method imputes missing threshold results
(two by two tables) by randomly selecting from the set of all possible
discrete combinations which lie between the results for two known
bounding thresholds. Imputed and observed results are then synthe-
sised in a bivariate meta-analysis at each threshold separately. This is
repeated M times, and the M pooled results at each threshold are
combined using Rubin’s rules to give final estimates.
Results: Compared to the standard NI approach, our simulations
suggest both SI and MIDC approaches give more precise pooled
sensitivity and specificity estimates, due to the increase in data.
Coverage of 95% confidence intervals was also closer to 95%, with
the MIDC method generally performing best, especially when the
prevalence was low. This is primarily due to improved estimation of
the between-study variances. In situations where the linearity
assumption was valid in logit ROC space, and there was selective
reporting of thresholds, the imputation methods also reduced bias in
the summary ROC curve.
Conclusions: The MIDC method is a new option for dealing with
missing threshold results in meta-analysis of test accuracy studies,
and generally performs better than the current method in terms of
coverage, precision and, in some situations, bias. A real example will
be used to illustrate the method.
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Background
In meta-analyses of diagnostic test accuracy, routinely only one pair of
sensitivity and specificity per study is used. However, for tests based on
a biomarker often more than one threshold and the corresponding
values of sensitivity and specificity are known.
Methods
We present a new meta-analysis approach using this additional infor-
mation. It is based on the idea of estimating the distribution functions
Diagnostic and Prognostic Research 2017, 1(Suppl 1):7 Page 3 of 34
of the underlying biomarker within the non-diseased and diseased
individuals. Assuming a normal or logistic distribution, we estimate the
distribution parameters in both groups applying a linear mixed effects
model to the transformed data. The model accounts for both the
within-study dependence of sensitivity and specificity and between-
study heterogeneity.
Results
We obtain a summary receiver operating characteristic (SROC) curve
as well as the pooled sensitivity and specificity at every specific
threshold. Furthermore, the determination of an optimal threshold
across studies is possible through maximization of the Youden index.
The approach is demonstrated on a meta-analysis on the accuracy of
Fractional Exhaled Nitric Oxide (FENO) for diagnosing asthma.
Conclusion
Our approach uses all the available information and results in an esti-
mation not only of the performance of the biomarker but also of the
threshold at which the optimal performance can be expected.
O8
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Following a meta-analysis of test accuracy studies, the translation of
summary results into clinical practice is potentially problematic. The
sensitivity, specificity, and positive (PPV) and negative (NPV) predictive
values of a test may differ substantially from the average meta-analysis
findings, due to heterogeneity. Clinicians thus need more guidance:
given the meta-analysis, is a test likely to be useful in new populations
and, if so, how should test results inform the probability of existing dis-
ease (for a diagnostic test) or future adverse outcome (for a prognostic
test)? In this presentation, we propose ways to address this [1].
Firstly, following a meta-analysis we suggest deriving prediction
intervals and probability statements about the potential accuracy of
a test in a new population. Secondly, we suggest strategies for how
clinicians should derive post-test probabilities (PPV and NPV) in a
new population based on existing meta-analysis results, and propose
a cross-validation approach for examining and comparing their
calibration performance. Application is made to two clinical exam-
ples. In the first, the joint probability that both sensitivity and specifi-
city will be > 80% in a new population is just 0.19, due to a low
sensitivity. However, the summary PPV of 0.97 is high and calibrates
well in new populations, with a probability of 0.78 that the true
PPV will be at least 0.95. In the second example, post-test probabil-
ities calibrate better when tailored to the prevalence in the new
population, with cross-validation revealing a probability of 0.97 that
the observed NPV will be within 10% of the predicted NPV. We recom-
mend that meta-analysts should go beyond presenting just summary
sensitivity and specificity results, by also evaluating and, if necessary,
tailoring their meta-analysis results for clinical practice [2].
We conclude with brief extension to the risk prediction modelling
field, where similar issues occur: in particular, the distribution of
model performance (e.g. in terms of calibration, discrimination and
net-benefit) should be evaluated across multiple settings, as focusing
only on summary performance can mask serious deficiencies [3].
References
1. Riley RD, Ahmed I, Debray TP, et al. Summarising and validating test
accuracy results across multiple studies for use in clinical practice. Stat
Med 2015; 34: 2081–2103.
2. Willis BH, Hyde CJ. Estimating a test’s accuracy using tailored meta-analysis:
How setting-specific data may aid study selection. J Clin Epidemiol
2014; 67: 538–546.
3. Snell KI, Hua H, Debray TP, Ensor J, Look MP, Moons KG, Riley RD.
Multivariate meta-analysis of individual participant data helped externally
validate the performance and implementation of a prediction model.
J Clin Epidemiol 2016; 69: 40–50
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Background: Test-treatment strategies are complex interventions in-
volving four main ingredients: 1) testing, 2) diagnostic decision–making,
3) therapeutic decision–making, 4) subsequent treatment. Methodolo-
gists have argued that it may be impossible to control for performance
bias when evaluating these strategies using RCTs, since test results must
be used by clinicians to plan patient management whilst patients are
often actively involved in testing processes and treatment selection.
Analysis of complex therapeutic interventions has shown blinding is not
always feasible, however claims regarding the ability to blind in test-
treatment trials have not been evaluated.
Aim: This methodological review analysed a systematically–derived
cohort of 103 test-treatment trials to determine the frequency of
blinding, and feasibility of blinding care–providers, patients and
outcome assessors.
Methods: Judgments of feasibility were based on subjective assess-
ments following previously published methods1. Extraction and
judgements were completed in duplicate, with final judgement deci-
sions made as a group consensus consisting of methodologists and
clinicians.
Provisional results: Care–providers, patients and outcome assessors
were masked by 4%, 5% and 22% of trials, and could have been
masked by a total of 11%, 50% and 66% respectively (Fig. 2). Scarcity
of attempts to blind reflected the practical and ethical difficulties in
performing sham diagnostic procedures, or masking real test results
from patients and clinicians. Feasibility hinged on: the types of tests,
nature of their comparison, type of information produced and cir-
cumstances surrounding their administration.
Conclusions: These findings present worrying implications for the
validity of test-treatment RCTs. Unexpectedly we found that in some
circumstances blinding may alter or eliminate the desired test–treat
effect, and recommend further investigation to determine the true
impact of masking in these highly complicated trials.
Reference
1. Following method of Boutron et al. J Clin Epidemiol 2004;57:543–550
Fig. 2 (abstract O9). The feasibility of blinding patients, care-providers
and outcome assessors in test-treatment RCTs
Diagnostic and Prognostic Research 2017, 1(Suppl 1):7 Page 4 of 34
O10
Measuring the impact of diagnostic tests on patient management
decisions within three clinical trials
Sue Mallett1, Stuart A. Taylor2, Gauraang Batnagar2, STREAMLINE COLON
Investigators2, STREAMLINE LUNG Investigators2, METRIC Investigators2
1Institute of Applied Health Research, University of Birmingham,
Birmingham, UK; 2Centre for Medical Imaging, University College
London, London, UK
Correspondence: Sue Mallett (s.mallett@bham.ac.uk)
Diagnostic and Prognostic Research 2016, 1(Suppl 1):O10
Background: Standard studies comparing diagnostic tests measure
diagnostic test accuracy. Some trials also provide information on add-
itional outcomes such as time to diagnosis and differences between
the number of additional tests in patient pathway. Ideally diagnostic
tests would be compared as interventions in randomised controlled
trials (RCTs). However RCTs for comparison of diagnostic tests as inter-
ventions can be problematic to design and run. Problems include long
time periods required for studies following patient outcomes during
which either test or treatment pathways change, high numbers of pa-
tients required, high costs, ethical issues about randomising to receive
tests, difficulty to understand role of diagnostic test as complex inter-
vention, plus other barriers. However for some tests it may be possible
to measure how tests affect patient management decisions within
current diagnostic accuracy trials.
Aims: To describe three ongoing clinical trials measuring the impact
of diagnostic tests on patient management.
Methods: Three trials, each comparing alternative diagnostic tests or
diagnostic test pathways against a reference standard of normal clinical
practice have been designed to collect patient management decisions.
In each patient management decisions based on the alternative path-
ways are reported based on eight or ten alternative management op-
tions. STREAMLINE COLON and LUNG compare whole body MRI to
current NICE recommended pathways for detection of metastases at
diagnosis of colon and lung cancer respectively. METRIC compares
ultrasound and MRI for diagnosing the extent and activity of Crohn’s
disease in newly diagnosed and relapsed patients.
Discussion of bias and applicability: Including patient management
decision into diagnostic accuracy studies increases understanding
when comparing the role of diagnostic tests. Including patient manage-
ment decision making can be onerous to collect in terms of clinical and
trialist time. Reduction of bias through blinding of test results and pa-
tient management decisions between test pathways being compared,
may only be achieved when patient management decisions are made
outside of normal clinical pathways. However the most applicable
decisions of patient management will be made by normal treating
clinicians within normal clinical pathways, when blinding of both
test results to each other is less feasible. Constraints of timing and
personnel mean trialists may be choosing between trial designs at
risk of bias with high applicability or at low risk of bias but high risk
of clinical applicability. More methodology work on including patient
management decisions based on diagnostic tests is required to under-
stand best ways to design studies and to understand robustness and
realism of different methods.
O11
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Background
Newborn blood spot screening involves taking a spot of blood from a
baby’s heel in the first 7 days of life, and testing for a range of rare dis-
orders using Tandem Mass Spectrometry. It is not possible to conduct
randomised controlled trials of screening for these rare diseases, so
decisions about which disorders to include must be made in the ab-
sence of such evidence. In this study we evaluated how the evidence is
used to make national policy decisions about which diseases to include
in the newborn blood spot test.
Methods
In the absence of RCT evidence, the evidence can be linked together to
understand probable patient outcomes. We developed a framework of
pathways to patient outcomes building on the work of Raffle and Gray,
Harris et al., and Adriaensen et al. in screening, and di Ruffano et al. in
test evaluation. We systematically reviewed the literature to identify
national screening decision making organisations, their criteria and pro-
cesses of decision making, and all policy and review documents related
to the Newborn blood spot test with no time limits. For each country
we analysed how the evidence for each patient pathway and outcome
had been considered in practice.
Results
There was large variation between countries, the median number of
disorders included in the newborn blood spot test was 19, ranging
from 5 in Finland to 54 in the US. Methods of deciding which disorders
to include involved expert panel consensus without formal evidence re-
view (Netherlands), systematic review with meta-analysis and economic
modelling (UK), and using recommendations and reviews from other
countries (Italy). Key elements of pathways to patient outcomes in-
cluded test accuracy, treatment benefit of early detection, and overdi-
agnosis. While 8/15 countries considered potential overdiagnosis in at
least one review, only 1/15 (the UK) attempted to quantify the numbers
overdiagnosed, and this used a comparison of prevalence between
countries with and without screening which is subject to significant
bias. Complete results by country by disease for pathways to patient
outcomes covered, evidence review methods, and association between
these and policy decisions will be available in time for the conference.
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Background
NICE has been producing guidance on medical diagnostic technolo-
gies since 2011. This has so far resulted in 24 pieces of guidance on
wide-ranging topics. As part of the process of reviewing its methods,
the pieces of guidance and the underpinning evidence are being
examined to inform thinking on potential future developments. The
expectation in diagnostics assessments is that end-to-end (E2E) stud-
ies, directly linking test use to patient outcome, such as comparative
outcome studies like RCTs, are rarely available and so there will be a
greater reliance on economic modelling as the main tool to assess
whether the diagnostic technology is effective and cost-effective.
This study reports findings on the availability, nature and impact of
any E2E studies informing the guidance so far.
Objectives
 To identify how many pieces of NICE diagnostics guidance
were informed by E2E studies
 Where E2E studies were found, to describe their nature
 To describe how the E2E studies informed committee
discussions and the final guidance
Methods
The approach was a document analysis of all pieces of published
diagnostics guidance and the underpinning evidence. A data
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extraction form was developed and piloted on one of the pieces of
diagnostics guidance and its underpinning evidence. Extraction was
performed by one researcher and checked by a second. Data was
tabulated and conclusions derived from the tables produced.
Main results
Although identifiable, the number of E2E studies could often not be
quickly located in either the under-pinning reports or the guidance. 11/
24, 46% (95% CI 26, 66) of guidance had any E2E studies, but in three
of these the numbers were very small. The E2E studies were mostly
RCTs. Where the test in the guidance was used for diagnosis, there was
a mean of 1.9 E2E studies and where used for monitoring there was a
mean of 12.2 E2E studies. The difference was unlikely to have occurred
by chance alone (Wilcoxon Mann-Whitney Test U = 20 p < 0.05). In the
guidance where there were substantial numbers of RCTs, clear account
was taken of them as evidenced by the amount of space devoted to
them in the “Outcomes” and “Considerations” sections
Authors’ conclusions
End-to-end studies are already an important part of the evidence base
in the assessment of diagnostic technologies. HTA methods need to
anticipate the likely continuing growth of these study types.
O13
Use of decision modelling in economic evaluations of diagnostic
tests: an appraisal of Health Technology Assessments in the UK
since 2009
Yaling Yang1, Lucy Abel1, James Buchanan1, Thomas Fanshawe1,
Bethany Shinkins2
1Nuffield Department of Primary Health Care Sciences, University of
Oxford, Oxford, UK; 2Academic Unit of Health Economics, Leeds Institute
of Health Sciences, University of Leeds, Leeds, UK
Correspondence: Yaling Yang (yaling.yang@phc.ox.ac.uk)
Diagnostic and Prognostic Research 2016, 1(Suppl 1):O13
Background: Diagnostic tests play an important role in the clinical
decision-making process by providing information that enables
patients to be stratified to the most appropriate treatment and
management strategies. Timely and accurate diagnosis is therefore
crucial for improving patient outcomes. By synthesising evidence
from multiple sources, decision analytic modelling can be used to
evaluate the cost-effectiveness of diagnostic tests in a comprehensive
and transparent way.
Objectives: This study critically assesses the methods currently used
to model the cost-effectiveness of diagnostic tests in Health Technol-
ogy Assessment (HTA) reports published in the UK, and highlights areas
in need of methodological development.
Methods: HTA reports published from 2009 onwards were screened to
identify those reporting an economic evaluation of a diagnostic test
using decision modelling. Existing decision modelling checklists
were identified in the literature and reviewed. Based on this review
a modified checklist was developed and piloted. This checklist cov-
ered 11 domains of good practice criteria, including:
 whether the decision problem is clearly defined and the
analytical perspective specified
 whether the comparators are appropriate given the scope
 whether the model structure is justified and reflects the natural
progress of the condition and available treatment options
 whether the inputs are consistent with the stated perspective
 whether sources of parameter values are systematically
identified, clearly referenced, and appropriately synthesised
 whether model assumptions are discussed
 whether appropriate sensitivity analyses are performed
A scoring system was then applied, with marks of ‘0, 0.5 and 1’ indicat-
ing that criteria were ‘not met, partially met, and met’, respectively. The
results were analysed and summarised to demonstrate to what extent
the HTA reports meet the quality criteria, and identify any outstanding
challenges.
Results and conclusions: A total of 484 HTA reports have been pub-
lished since 2009, of which 38 met the inclusion criteria. The reports
covered a variety of conditions including cancers, chronic diseases,
acute diseases and mental health conditions. The diagnostic tests in-
cluded lab-based, genetic and point-of-care tests, imaging, clinical risk
prediction scores, and quality of life measures. In general, the models
were of high quality with a clearly defined decision problem and
analytical perspective. The model structure was usually consistent with
the health condition and care pathway. However, the inherent com-
plexity of the models was rarely handled appropriately: limited justifica-
tion was provided for selection of comparators and few models fully
accounted for uncertainty in treatment effects. The analysis is ongoing
and full results will be presented in the paper.
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Purpose: To evaluate the clinical utility of prediction models to diag-
nose ovarian tumors as benign versus malignant using decision curves.
Methods: We evaluated the widely used RMI scoring system using a
cut-off of 200, and the following risk models: ROMA and three models
from the International Ovarian Tumour Analysis (IOTA) consortium (LR2,
SRrisks, and ADNEX). We used a multicenter dataset of 2403 patients
collected by IOTA between 2009 and 2012 to compare RMI, LR2,
SRrisks, and ADNEX. Additionally, we used a dataset of 360 patients
collected between 2005 and 2009 at the KU Leuven to compare RMI,
ROMA, and LR2. The clinical utility was examined in all patients, as well
as in several relevant subgroups (pre- versus postmenopausal, oncology
versus non-oncology centers).
We quantified clinical utility through the Net Benefit (NB). NB cor-
rects the number of true positives for the number of false positives
using a harm-to-benefit ratio. This ratio is the odds of the risk of
malignancy threshold at which one would suggest treatment for
ovarian cancer (e.g. surgery by an experienced gynaecological on-
cologist). A threshold of 20% (odds 1:4) implies that up to 4 false
positives are accepted per true positive. Using NB, a model can be
compared to competing models or to default strategies of treating
all or treating none. We expressed the difference between models
as gain in ‘net specificity (i.e., sensitivity for a constant specificity,
ΔNB/prevalence). 95% confidence intervals were obtained by
bootstrapping.
Results: Thresholds between 5% (odds 1:19) and 50% (odds 1:1) were
considered reasonable. RMI performed worst and was harmful, i.e.
worse than treat all, at thresholds <20%. ADNEX and SRrisks consist-
ently showed best performance (see Fig. 3). At the 10% threshold,
SRrisks’ net sensitivity was 4% (95% CI 3% to 6%) higher than that of
LR2, but similar to the net sensitivity of ADNEX (difference 0%, 95%
CI -1% to 1%). Subgroup results showed similar patterns. On the
second dataset, results for RMI were similar. In addition, LR2
performed best for the entire range of thresholds, and was the only
model with clinical utility at a risk threshold of 10%.
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Conclusions: NB supersedes discrimination and calibration to quan-
tify the clinical utility of prediction models. Our data suggest superior
utility of IOTA models compared to RMI and ROMA.
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Background: The accuracy of a diagnostic test should be compared
to the accuracy of its alternatives. Direct comparisons of tests, in the
same patients and against the same reference standard, offer the
most valid study design, but are not always available. Comparative
systematic reviews are therefore bound to rely on indirect compari-
sons. As the results from these comparisons can be biased, we inves-
tigated ways to correct for indirectness.
Methods: From a large systematic review about the accuracy of D-
Dimer testing for venous thromboembolism, we selected those com-
parisons between two assays that contained three or more direct
comparisons and four or more indirect comparisons or single assay
studies. Each comparison was analyzed using the bivariate random
effects meta-regression model with assay-type, directness and inter-
action between the two as covariates in the model. In comparisons
with a significant effect of the interaction term on sensitivity or spe-
cificity, we included the following study features to correct for these
differences: referral filter, consecutive enrolment, time-interval, one
or more reference standards, verification and year of publication.
Results: Seventeen comparisons were eligible for our analyses. In nine
of these, the direct comparisons showed a significant difference be-
tween test A and test B while the indirect comparisons did not; or vice
versa. However, the interaction term between assay and indirectness
showed a significant (P < 0.05) effect on logit-sensitivity and/or logit-
specificity in only four of them. Addition of study features as covariates
removed the significant effect of the interaction term in two meta-
analyses. In the first one, the interaction term was significant for sensitiv-
ity (P = 0.006), but after addition of the covariate ‘time-interval between
index test and reference standard’ and after addition of the covariate
‘year of publication’, the P-value became 0.086 and 0.096 respectively. In
the other analysis, the interaction term was significant for specificity (P =
0.039), but after addition of the covariate ‘all results verified’ and after
addition of the covariate ‘only one reference standard used’, the P-value
became 0.160 and 0.083 respectively.
Conclusions: Adjusting the effect of directness for study features
seems to be possible in some instances, but no systematic effects were
found. Study characteristics that may be influential in one comparison,
may have no influence at all in another comparisons.
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Introduction: Overdiagnosis is often described as the detection of
disease that will not progress to cause symptoms or premature
death. No consensus exists on the most appropriate method to esti-
mate overdiagnosis. At a population level it can be estimated using
incidence and mortality data with sufficient length of observation
to account for lead time. We examined incidence and mortality pat-
terns over the last 30 years for the most common cancers in Great
Britain, with the aim of developing a method to identify potential
overdiagnosis.
Methods: Mortality data were available since 1950 while incidence data
were obtained from 1979. We used log-linear regression to model the
long-term trend in age-standardised cancer-specific mortality rates for
the “pre-diagnostic era” (1950–78) and used these results to predict
both mortality and incidence rate in the “diagnostic era” (1980–2012).
We used current (“diagnostic era”) incidence and mortality data from
Cancer Research UK to calculate excess incidence and deaths avoided
by subtracting the observed rates from the predicted rates in ten can-
cers types for men and women separately. We used the ratio of excess
incidence to deaths avoided to summarise our findings.
Results: Simple straight-line models accounted for between 50 and
92% of variation seen in mortality rates in the pre-diagnostic era.
Mortality in the diagnostic era closely followed the predicted trends
except for breast cancer. In contrast, observed incidence was gener-
ally greater by several orders of magnitude to that predicted by the
model. Cumulative excess incidence ranged from between 16 cases
per 100,000 for thyroid cancer to 1763 per 100,000 for cervical
cancer. The model estimated the number of cumulative deaths
avoided as zero for the following cancers: oral (both men and
women), prostate (men), bowel (men) and kidney (women). For the
cancers where the ratio of excess incidence to deaths avoided
could be estimated, these ratios varied from 1:1 (non-Hodgkin’s
Lymphoma (NHL) in women) to 107:1 (Uterine in women).
Conclusions: The use of long-term mortality data may be useful for
identifying and quantifying overdiagnosis by ecological analysis.
Our results show that the incidence of many of the most common
cancers in Great Britain has increased significantly in the last three
decades but this has not necessarily prevented cancer deaths. We
suggest that much of the increased detection represents the over-
diagnosis of cancer.
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Fig. 3 (abstract O14). See text for description
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Background: Misplaced policy decisions about screening pro-
grammes may exist unless the decision process explicitly accommo-
dates the disutility of screening and treating individuals subject to
over-diagnosis. In breast cancer screening, radical surgery or radio-
therapy for a woman with an over-diagnosed result would impose
a serious unnecessary harm on that woman. At the individual level
the harm may not actually be realised because the woman may
never know that she had her breast removed unnecessarily. How-
ever, at a societal level these collective harms, if quantified, could
be included in the analysis and might serve to outweigh the bene-
fits of the screening programme. Recent evidence suggests the
benefits of screening programmes have been overstated but the
extent and duration of the loss of quality of life as a result of over-
diagnosis has been under-researched.
Objectives: To explore the hypothesis that the explicit inclusion of
potential disutility associated with the treatment of over-diagnosed
early breast cancers will change the relative cost-effectiveness of the
current recommended breast screening strategy.
Methods: Preliminary literature searches have shown that although
multiple utility health states exist for early and metastatic breast
cancers, there is significant heterogeneity between values and
limited research on quantifying values associated with the breast
screening programme itself. Little has been done to address the
problem of over-diagnosis in breast cancer screening or attempts
made to quantify associated losses in quality of life. A systematic
review of utility and disutility values associated with breast screen-
ing is carried out to inform the design of a pilot study devised to
capture the disutilities associated with over-diagnosis in screening
mammography.
Results: The review results and protocol for the primary work will be
completed by June. It is anticipated that women will report a loss in
utility associated with the screening process, in particular with false
positive mammograms, but limited numbers of such studies may
render pooling of these states problematic. Very few economic evalu-
ations of screening mammography explicitly include over-diagnosis
in their analysis.
Discussion: This study highlights the challenges of estimating and
incorporating the disutility of over-diagnosis in evaluations of
screening programmes. The results from the review and the pilot
study will be incorporated into a model based economic evalu-
ation of the breast screening programme to estimate losses in
quality of life associated with unnecessary treatment as a result of
over-diagnosis.
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Background: Stratified medicine has been defined as using predict-
ive biomarkers to identify cohorts of patients more likely to benefit
from a treatment (or less likely to experience a serious adverse
event). There are numerous successful predictive biomarkers that
have changed clinical practice. There are also examples where
potential predictive biomarkers failed at a late stage of develop-
ment (ERCC1 expression – platinum-based chemotherapy), or there
is uncertainty about their utility in spite of being introduced into
clinical practice (EGFR expression - erlotinib). These examples, to-
gether with the need to optimise the use of resources by prioritis-
ing research activities, suggest a structured approach to biomarker
development may be necessary. There is a well-established model
for phased evaluation of drugs, however no such model is in place
for predictive biomarkers. There have been various publications on
this topic both by research groups and institutions (such as the
FDA). However there is no accepted model and it remains unclear
whether there is consensus in the literature on the best approach
to staged evaluation of predictive biomarkers.
Aim: To identify existing frameworks for staged evaluation of predictive
biomarkers and the stages these propose. For the identified stages, to
explore the outcomes, relevant study designs and requirements for the
entry into and completion of each stage. To compare and contrast the
different frameworks and therefore identify requirements for develop-
ment of a predictive biomarker.
Methods: We have undertaken a systematic review of papers
suggesting a framework for staged evaluation of predictive bio-
markers. These were identified through broad searches of MEDLINE,
EMBASE and additional internet searches. The identified frameworks
were compared and grouped based on the context in which the
development of a predictive biomarker was discussed (for example
development of a biomarker predicting treatment safety) and the
stages proposed.
Findings: We identified 22 papers describing a framework for staged
evaluation of predictive biomarkers. These were grouped into four
models: (1) general predictive biomarker development, (2) integrated
into phased drug development, (3) development of a multi-marker
classifier and (4) development of marker predicting treatment safety. It
appeared that the most complete model was (1) general, which com-
prised stages: pre-discovery, discovery, analytical validation, clinical
validation, clinical utility, implementation. The remaining models mostly
contained stages corresponding to these, however models (2) and (3)
did not contain analytical validation and model (4) clinical validation.
The stages in models (2-4) corresponding to those in model (1) were
occasionally merged or divided into multiple stages. Different termin-
ology was also used to describe similar concepts. Relevant study
designs were described for all stages, however there seemed to be
consensus mainly for the clinical utility stage, where generally RCTs
designed to evaluate the biomarker were suggested (including enrich-
ment, stratified and biomarker-strategy designs).
Conclusions: The identified models suggest the need to consider the
context in which the biomarker is developed. There was a large overlap
between the four models, suggesting consensus on at least some of
the research steps that may be necessary prior to predictive biomarker
implementation into clinical practice.
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Introduction: To use a test to the best effect when monitoring disease
progression or recurrence of patients it is vital to have accurate infor-
mation regarding the variability of the test, including sources and esti-
mation of measurement error. There are many sources of variability
when testing a population. There is variability in the results for a single
patient even when in a stable disease state, this fluctuation in results is
within-individual variability, and there is also variability in results from
person-to-person which is known as between-individual variability.
When undertaking a test, there is pre-analytical variability which occurs
before the test is analysed, including within-individual and between-
individual variations e.g. timing of measurement. Analytical variation
is the variability in test results during the process of obtaining the
result, such as when a sample is assayed in a laboratory test. Where
interpretation of tests can be subjective, there are intra-inter reader
studies to assess variability, comparing interpretations from multiple
observers.
Objectives: To review the current state of variability studies for tests
to identify best methods and where studies could be improved. Our
research focusses on design, sample size, methods of analysis and
quality of studies.
Methods: To understand the scope of studies evaluating biological
variability, the design, methods for analysis, reporting and overall
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quality, a review of studies of biological variation was conducted
and, whilst conducting this review, the key methodological papers
influencing these studies were identified. The searches used to iden-
tify papers to be included in the review were: key word search (bio*
AND vari*) for the period 1st November 2013 to 31st October 2014;
all articles published in the journals Clinical Biochemistry, Radiology
and Clinical Chemistry during the period 1st January 2014 to 31st
December 2014; papers included in the Westgard QC database pub-
lished from 1st January 2000 onwards; and, detailed searches for
three different test types (imaging, laboratory and physiological) in
specific clinical areas: ultrasound imaging to assess bladder wall
thickness in patients with incontinence; creatinine and Cystatin C
measurements to estimate glomerular filtration rate (GFR) in patients
with chronic kidney disease (CKD); and, spirometry to measure forced
expiratory volume (FEV) in patients with chronic obstructive pulmon-
ary disorder (COPD). In addition to the papers identified by these
searches, published articles identified by previous and concurrent
work meeting the criteria were included to enrich the sample.
Key information regarding the design, analysis and results reported
was extracted from each paper. In addition, analyses of data from a
biological variability study were conducted to demonstrate the
current framework for design and analysis and investigate the impact
of various components within this.
Results: The review identified 106 studies for assessment allowing
the current state of the field with regard to design, analysis and
reporting to be evaluated. We will present our findings on typical
designs including examples of patient recruitment, sample sizes,
analysis methods and sources of variability addressed.
Conclusions: This work will identify the current state of the method-
ology in this area to help identify where future work to improve the de-
sign, analysis and reporting of biological variability studies is needed.
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Purpose: Any quantitative measurement procedure needs to be
both accurate and reliable in order to justify its use in clinical prac-
tice. Reliability concerns the ability of a test to distinguish patients
from each other, despite measurement errors, and is usually
assessed by intraclass correlation coefficients (ICC). Agreement, on
the other hand, focuses on the measurement error itself, and various
parameters are used in practice, comprising proportions of agreement,
standard errors of measurement, coefficients of variations, and Bland-
Altman plots. We revive variance component analysis (VCA) in order to
decompose the observed variance attributable to different sources of
variation (e.g. rater, scanner, time point), to derive relevant repeatability
coefficients (RC), and to show the connection to Bland-Altman plots in
a test-retest setting. Moreover, we propose a sequential sample size
strategy when assuming differences in a test-retest setting to follow ap-
proximately a Normal distribution.
Methods: Variants of the commonly used standard uptake value
(SUV) in cancer imaging from two studies at our institution were
used. In study 1, thirty patients were scanned once pre-operatively
for the assessment of ovarian cancer. These 30 images were assessed
two times by the same rater two months apart. In study 2, fourteen
patients with a confirmed diagnosis of glioma were scanned up to 5
times before and during treatment, and the resulting 50 images were
assessed by three raters. Studies 1 and 2 served as examples for
intra- and interrater variability assessment, respectively. In study 1,
we treated ‘reading’ (1st vs. 2nd) as fixed factor and ‘patient’ as ran-
dom factor. In study 2, both ‘rater’ and ‘time point’ were considered
fixed effects, whereas ‘patient’ and ‘scanner’ were treated as random
effects. The sequential sample size strategy, post hoc applied to data
from study 1, was based on a hypothesis test on the population
variance of the differences between measurements, assuming that
the differences follow a Normal distribution. An overall recruitment
plan of 15 + 15 + 20 patients was assumed, and the adjustment for
multiple testing was done by applying a α-spending function accord-
ing to Kim, DeMets (Biometrika 1987).
Results: In study 1, the within-subject standard deviation times 2.77
resulted in a RC of 2.46, which is equal to the half width of the
Bland-Altman band. The RC is the limit within which 95% of differ-
ences will lie. In Study 2, the RC for identical conditions (same
patient, same rater, same time point, same scanner) was 2392,
allowing for different scanners resulted in a RC of 2543. The differ-
ences between raters were, though, negligible compared to the
other factors: estimated difference between reader 1 and 2: -10,
95% CI: -352 to 332; reader 1 vs. 3: 28, 95% CI: -313 to 370. The ad-
justed significance levels for the tests conducted with 15 and 30
patients, respectively, were 0.015 and 0.03. Investigating a range of
hypothetical population variance values of 0.25, 0.5, …, 4 resulted
in rejecting the one-sided null for 3 at both stages.
Conclusion: VCA seems to be an obvious, yet intriguing approach to
agreement studies which often are tackled with simple measures
only. VCA is, indeed, built upon various model assumptions, but that
had been neither obstacle to the wide use of ICCs in reliability
analysis. The ice is getting even thinner when basing the sample size
strategy on population variance tests (and the normality assumption),
which, though, could be applied in an adaptive manner in the same
way as it is often done in therapeutic trials.
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The need of laboratories to quickly assess the quality of samples
leads to the development of new methods, and improvement of
existing methods. It is hoped that these will be more accurate than
the reference method. To be validated, these alternative methods
should lead to results comparable (equivalent) with those obtained
by a standard method.
Two main methodologies for assessing equivalence in method-
comparison studies are presented in the literature. The first one is
the well-known and widely applied Bland–Altman approach with its
agreement intervals, where two methods are considered inter-
changeable if their differences are not clinically significant. The
second approach is based on errors-in-variables regression in a
classical (X,Y) plot and focuses on confidence intervals, whereby
two methods are considered equivalent when providing similar
measures notwithstanding the random measurement errors. This
research reconciles these two methodologies and shows their simi-
larities and differences using both real data and simulations. New
consistent correlated-errors-in-variables regressions are introduced
as the errors are shown to be correlated in the Bland–Altman plot.
Indeed, the coverage probabilities collapse and the biases soar
when this correlation is ignored. Robust novel tolerance intervals
are compared with agreement intervals, and novel predictive inter-
vals are introduced with excellent coverage probabilities.
We conclude that the (correlated)-errors-in-variables regressions should
not be avoided in method comparison studies, although the Bland–Alt-
man approach is usually applied to avert their complexity. We argue
that tolerance or predictive intervals are better than agreement
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intervals. It will be shown that tolerance intervals are easier to calculate
and easier to interpret. Guidelines for practitioners regarding method
comparison studies will be discussed.
Reference
1. Francq, B. G., and Govaerts, B. (2016) How to regress and predict in a
Bland–Altman plot? Review and contribution based on tolerance
intervals and correlated-errors-in-variables models. Statist. Med.,
doi: 10.1002/sim.6872
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Background: Monitoring tests can be used to identify disease recur-
rence or progression. Monitoring strategies are complex interventions,
involving specification of a test, a schedule, a threshold or decision rule
based on test results, and subsequent diagnostic or therapeutic action.
Before undertaking an RCT of a monitoring strategy all four of these
components of the monitoring intervention need to be defined. Excess
false positives and potentially unnecessary interventions can be caused
by using a poorly discriminating or imprecise test, monitoring too fre-
quently, or choosing to act at too low a threshold.
Aim: The study focused on evaluating monitoring strategies using
the ELF test to detect progression of fibrosis to decompensated cir-
rhosis in patients with severe liver disease. The study had two aims:
(1) To use early modelling to predict performance of the ELF test for
different monitoring schedules and thresholds; (2) To validate the
modelling by comparison with results from an RCT of the monitoring
strategy.
Methods: A simulation model was constructed using evidence from
the literature, existing data sources and expert opinion to inform dis-
ease progression, relationship of the marker with the disease state,
and measurement error in the marker. The test schedule and deci-
sion rule were varied to identify optimal strategies. The ELUCIDATE
RCT randomized 878 patients to an ELF based monitoring strategy or
usual care, and was undertaken at the same time as the modelling.
Data from the RCT are now available on process of care outcomes,
disease based outcomes will be available in the future. Comparisons
are made between predictions from the simulation model and results
of the trial.
Results: Identifying data to build the simulation model was challen-
ging, particularly concerning test characteristics. The simulation model
demonstrated that the performance of the monitoring strategy was
most influenced by estimates of disease progression, measurement
error of the test and the test threshold. The test strategy as used in the
ELUCIDATE trial was predicted to lead to high rates of early interven-
tion, which was then observed in the trial in terms of numbers of
patients being referred for further investigation in the monitoring arm
than in usual care.
Conclusion: Early modelling of monitoring strategies is recommended
prior to undertaking RCTs of monitoring strategies to assist in determin-
ing optimal test thresholds and frequencies. The study highlights the
importance of obtaining valid data on both the performance of the test
and the progression of disease before planning trials.
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Introduction: Usual methods to estimate diagnostic accuracy of
index tests in the presence of an imperfect reference standard result
in biased accuracy and prevalence estimates. The latent class model
(LCM) methodology deals with imperfect reference standard by
statistically defining the true disease status and possibly assuming re-
sidual dependences between diagnostic tests conditionally on this
status. Different dependence specifications can lead to inconsistent
accuracy estimates, therefore thorough evaluation of models should
be systematically undertook although this is rarely done in practice.
We use the study of new campylobacter detection tests in which
bacteriological culture is an imperfect reference standard to illustrate
the complexity of the implementation of a LCM methodology to as-
sess the diagnostic accuracy of detection tests.
Methods: Five tests of campylobacter infection (bacteriological culture,
one molecular test and three immunoenzymatic tests) were applied to
stool samples of 623 symptomatic patients at Bordeaux and Lyon Uni-
versity Hospital in 2009. Their sensitivity and specificity were estimated
with LCMs using maximum likelihood method after probit or logit
transformations. Conditional independence hypothesis between tests
was relaxed by specifying alternative dependence structures based on
random effects. Performances of the models were compared using in-
formation criteria, goodness-of-fit statistics with asymptotic or empirical
distributions (to tackle many rare or missing profiles) and bivariate re-
sidual statistics. Two main functions implementing LCMs were used:
NLMIXED procedure in SAS® and randomLCA package in R.
Results: Among the 25 = 32 theoretical profiles of test responses, 17
were observed including 10 with 3 patients or more. The model under
conditional independence hypothesis presented the worst Akaike infor-
mation criterion (AIC) and was highly rejected by all statistics. Introdu-
cing a random effect common to all diagnostic tests improved the AIC
but the model was still rejected by nearly all statistics. Among the other
dependence structures evaluated, the model assuming a residual de-
pendence between the three immunoenzymatic tests showed the best
AIC. Statistics using empirical distributions were just above the signifi-
cance level (p > 0.05) except for the total bivariate residual statistics
(p = 0.03). With this model, prevalence of campylobacter infection
was 0.11. As expected, culture presented the lowest sensitivity (82.1%
vs 85.2%–98.5% for other tests) and the highest specificity (99.6% vs
95.8%–98.4% for other tests). When evaluated by simulations, perfor-
mances of NLMIXED procedure for the random effect shared by all
diagnostic tests showed low coverage rates while randomLCA package
provided correct inferences.
Conclusion: LCM methodology allowed estimating the diagnostic ac-
curacy of new campylobacter detection tests and of culture which is
an imperfect reference standard as confirmed by our results. Model
assessment steps are crucial to select the best specification in LCM
and get valid accuracy estimates. However, their interpretation is
tricky because of discordant conclusions depending on the statistics
used. Rare or missing profiles are frequent when diagnostic tests
present high accuracy making use of asymptotic distributions inad-
equate. Statistics using empirical distributions therefore need to be
specifically implemented. Lastly, usual softwares can have limitations
due to their unreliability (NLMIXED) or lack of flexibility (randomLCA).
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Despite efforts to determine the presence or absence of the condition
of interest in all participants in a diagnostic accuracy study, missing ref-
erence standard results (i.e. missing outcomes) are often inevitable and
should be anticipated in any prospective diagnostic accuracy study.
Analyses that include only the participants in whom the reference
standard was performed are likely to produce biased estimates of
the accuracy of the index tests. Several analytical solutions for deal-
ing with missing outcomes are available; however, these solutions re-
quire knowledge about the pattern of missing data, and they are no
substitute for complete data.
In this presentation we aim to provide an overview of the different
patterns of missing data on the reference standard (i.e. incidental
missing data, data missing by research design, data missing due to
clinical practice, data missing due to infeasibility), the recommended
corresponding solutions (i.e. analytical correction methods or includ-
ing a second reference standard), and the specific measures that can
be taken before and during a prospective diagnostic study to en-
hance the validity and interpretation of these solutions. In the pres-
entation various examples will be discussed.
Researchers should anticipate the mechanisms that generate missing
reference standard results before the start of a study, so that mea-
sures and actions can explicitly be taken to reduce the potential for
biased estimates of the accuracy of the tests, markers, or models
under study, as well as to facilitate correction in the analysis phase.
In all cases, researchers should include in their study report how
missing data on the index test and reference standard were handled,
as invited by the STARD reporting guideline.
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Background: Continuous predictors are routinely encountered when
developing a prognostic model. Categorising continuous measure-
ments into two or more categories has been widely discredited.
However, it is still frequently done when developing a prognostic
model due to its simplicity, investigator ignorance of the potential
impact and of suitable alternatives, or to facilitate model uptake.
Methods: A resampling study was performed to examine three broad
approaches for handling continuous predictors on the performance
of a prognostic model: 1. Multiple methods of categorising predictors
(including dichotomizing at the median; categorising into 3, 4, 5,
equal size groups; categorising age only into 5 and 10-year age
groups), 2. modelling a linear relationship between the predictors
and outcome, and 3. modelling a nonlinear relationship using frac-
tional polynomials or restricted cubic splines. Using the THIN dataset,
we used primary care general practice data (from England) to
develop models using Cox regression to predict a) the 10-year risk of
cardiovascular disease (n = 1.8 million) and b) 10-year risk of hip
fracture (n = 1 million). We also examine the impact of sample in
developing the prognostic models on model performance (using
data sets with 25, 50, 100 and 2000 outcome events). We compare
the performance (measured by the c-index, calibration and net bene-
fit) of prognostic models built using each approach, evaluating them
using separate data from Scotland.
Results: Our results show that categorising continuous predictors
produces models with poor predictive performance (calibration and
discrimination) leading to limited clinical usefulness (net benefit). A
large difference of between the mean c-index produced by the
approaches (as large as 0.1 for the hip fracture model) that did not
categorise the continuous predictors and the approach that dichoto-
mised the continuous predictors at the median. The calibration of
the models was poor for all methods that used categorisation, which
was further exacerbated when the models were developed on small
sample sizes. Over a range of clinically relevant probability thresh-
olds, an additional net 5 to 10 cardiovascular disease cases per 1,000
were found during validation if models that implemented fractional
polynomials or restricted cubic splines were used, rather than models
that dichotomised all of the continuous predictors at the median
without conducting any unnecessary treatment. The models that
used fractional polynomials or restricted cubic splines (no difference
between the two nonlinear approaches), or that assumed a linear rela-
tionship between the predictor and outcome all showed a higher net
benefit, over a range of thresholds, than the categorising approaches
Conclusions: Categorising continuous predictors is unnecessary, bio-
logically implausible and inefficient and should not be used in prog-
nostic model development.
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Background: Clinical risk prediction models are increasingly being
developed and validated on multicenter datasets. We investigate
how the choice of modeling technique affects the predictive per-
formance of the model, and whether this effect depends on the level
of validation.
Method: We present a comprehensive framework for the evaluation
of the predictive performance of prediction models at both the cen-
ter level and the population level, considering population-averaged
predictions, center-specific predictions and predictions assuming
average center effects. We sampled large (100 events per variable)
datasets from simulated source populations (n = 20,000, 20 centers)
with strong clustering (intraclass correlation 20%). A random inter-
cept (RI) model and a standard logistic regression (LR) model were
built in each sample. The agreement between predicted and ob-
served risks was evaluated in the remainder of the source population
using the calibration slope, which ideally equals 1, the calibration
intercept, which ideally equals 0, and the c-statistic.
Results: Predictions from the RI model assuming average center
effects were well calibrated within clusters (β^
cal within
¼ 0:98) but
too extreme at the population level (β^
cal
¼ 0:88). Center-specific
predictions from the RI model were well calibrated within clusters
( β^
cal within
¼ 0:99 ) and at the population level ( β^
cal
¼ 0:98 ).
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Population-averaged predictions from the standard LR model were not
extreme enough for within-cluster calibration (β^
cal within
¼ 1:09) but
were well calibrated at the population level ( β^
cal
¼ 0:99). We show
that this pattern is explained by the well-known difference between
marginal and conditional effects[1]. The same pattern was observed for
the calibration intercepts, with miscalibration of the predictions assum-
ing an average center effect at the population level and of the
population-averaged predictions at the cluster level. The c-statistic at
the population level was higher for center-specific predictions (C =
0.815) than for average center predictions and population-averaged
predictions (Cs = 0.764). At the cluster level, all c-statistics were the
same (Cwithin = 0.785).
Conclusion: We recommend that model development (standard vs RI
model) reflects the data structure, while the level of model validation
(cluster level vs population level) reflects the research question. Gener-
ally, center-specific predictions offer the best population-level and
center-level calibration and discrimination. However, center-specific
predictions are not available for patients from new centers. Population-
averaged predictions are a good alternative when population-level cali-
bration is required, while predictions assuming an average center effect
are a good alternative when center-level calibration is required.
Reference
1. Zeger SL, Liang K-Y, Albert PS: Models for Longitudinal Data: A General-
ized Estimating Equation Approach. Biometrics 1988, 44(4):1049–1060.
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Background and objectives: Prognostic models are, among other
things, used to provide risk predictions for individuals who are not
receiving a certain treatment, in order to assess the natural course of
a disease and in turn guide treatment decisions. As treatment avail-
ability and use changes over time, researchers may be faced with
assessing the validity of existing models in partially treated popula-
tions, and may account for treatment use in different ways. We
aimed to investigate how treatment use contributes to the poor per-
formance commonly observed in external validation studies, and to
explore methods to address the issue.
Methods: The effect of treatment use on the observed performance
of a model was evaluated analytically. Development data sets repre-
senting untreated individuals were simulated using a logistic model
and “optimal” models were developed using those sets. Validation
sets drawn from the same theoretical population were simulated to
receive an effective (binary) treatment. The prevalence and effective-
ness of treatment were varied, with and without being dependent
on true risk. Model performance in the validation sets was expressed
in terms of calibration slope, observed:expected ratio (O:E) and C
statistic. We examined the results of i) ignoring treatment, ii) restrict-
ing validation to untreated patients, and iii) adjusting the observed
event rates to account for treatment effects. This was expressed
through the difference (Δ) between each performance measure after
applying a method and the value observed in the untreated set.
Results: Validation of a model derived in untreated individuals in a
treated validation set resulted in poorer model performance than
that observed in the same population, if left untreated. Treatment of
50% of patients with a highly effective treatment (higher risk patients
had a higher probability of receiving treatment; treatment effect
odds ratio: 0.5), resulted in a decrease in the O:E from 1.0 to 0.7, and
a decrease in the C statistic from 0.67 to 0.62 when compared to the
observed statistics in an untreated set. This trend was observed
across settings with different mechanisms for treatment allocation
and different population risk distributions. As treatment prevalence
and effectiveness increased, the observed model performance al-
most invariably decreased. Restricting the validation to only un-
treated individuals resulted in performance measures closer to
those observed in the full untreated validation set, at the cost of
precision (Δ O:E = 0.0; C statistic = 0.03). When treatment allocation
was completely based on risk (I.e. according to a risk threshold), the
restriction approach was less effective (ΔO:E = 0.0; ΔC statistic =
0.07). Increasing the observed event rates to account for treatment
effects improved the observed model calibration, but this was
highly sensitive to incorrect assumptions about treatment use and
effectiveness.
Conclusions: Validating a model designed to make predictions of the
“natural course” of an individual’s health in a validation data set con-
taining treated individuals may result in an underestimation of the
performance of the model in untreated individuals. Current methods
are not sufficient to account for the effects of treatment, and findings
from such studies should be interpreted with caution.
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Background and objective. Calibrated risk models are vital for valid
decision support. However, definitions and approaches to investigate
calibration vary. We define a hierarchy of calibration definitions and
describe implications for model development and external validation
of predictions, with a specific focus on model utility and sample size.
Study design and methods. We present results based on simulated
datasets, assuming a multivariable prediction model for a dichotom-
ous outcome based on logistic regression.
Results. At the bottom of the calibration hierarchy is ‘mean calibra-
tion’ or calibration-in-the-large, which only requires that the average
predicted risk corresponds to the observed event rate. Next, ‘weak
calibration’ or logistic calibration requires the average prediction ef-
fects to be correct, implying a calibration slope of 1 and a calibration
intercept of 0. This level is by definition achieved on the develop-
ment data when standard maximum likelihood is used. ‘Moderate
calibration’ refers to the common definition of calibration as “having
an event rate of R% among patients with a predicted risk of R%”. This
implies that the flexible calibration curve lies on the diagonal. At the
top of the hierarchy is ‘strong calibration’, which requires that the
event rate equals the predicted risk for every covariate pattern based
on the model predictors. In fact, this implies that the model is fully
correct for the validation setting. We argue that this is unrealistic: the
model type (e.g. the logit link) may be incorrect, at model develop-
ment the linear predictor is only asymptotically unbiased, and all
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nonlinear and interaction effects should be correctly modeled. We
prove that moderate calibration already guarantees non-harmful
decision-making. Finally, results indicate that a flexible assessment of
calibration in small validation datasets is problematic. We updated
the val.prob function of Harrell’s rms package for R.
Conclusion. Strong calibration is desirable for individualized decision
support, but unrealistic and counter-productive by stimulating the
development of overly complex models. Model development and ex-
ternal validation should focus on moderate calibration.
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Background & rationale: The National Screening Committee as of
January 2016 have recommended a change from the guaiac based
faecal occult blood test (FOBT) to the more accurate faecal immuno-
chemical test (FIT) in the UK following a successful Bowel Cancer
Screening Programme (BCSP) pilot study. The increased uptake and
test positivity demonstrated from this pilot however will challenge
current colonoscopy capacity and countries will need to set the posi-
tivity threshold accordingly. The FIT has the advantage of an adjust-
able positive threshold and provides a quantitative haemoglobin
concentration which relates to the risk of colorectal cancer (CRC). Risk
scoring systems which combine the FIT concentration with individ-
ual risk factors have been shown to improve the sensitivity of the
test and the cancer detection rate compared to using the screening
test alone. For instance, a study in the Netherlands combined risk
factors with the FIT result and showed improved sensitivity at a
similar level of specificity but no such study currently exists for the
UK population.
Research aim: The purpose of this study is to determine whether
integrating routinely available predictors from the Bowel Cancer
Screening System (BCSS) with the FIT result improves test
performance.
Methods: This will be achieved using data collected for the FIT pilot
study which took place April to October 2014. There were 40,930 in-
dividuals who were invited to take part in the study from the Mid-
lands and Southern hubs with 27,167 returning a FIT. Predictive
models will be developed initially using logistic regression. The first
model will use the FIT result alone as a predictor of CRC and the sec-
ond will use both the FIT result and the additional predictors avail-
able on the BCSS including; age, gender, IMD (from postcode),
screening history and previous results. These models will be com-
pared using model performance measures such as calibration and
discrimination and test performance will be investigated by produ-
cing ROC curves and determining whether sensitivity at set specifi-
city is improved. The model will then be developed further using
more complex statistical techniques, including neural networks, to
take into account potential non-linear associations.
Relevance, application and benefits: A risk based approach to
screening may have several benefits for both patients and for the
screening programme including an increased detection of early stage
cancers and their precursors as well as minimising the number of
false positives and false negatives. In addition, colonoscopies are an
expensive and limited resource and carry their own risks for patients.
This approach would aim to refer those at higher risk for colonos-
copy and place those at lower risk back into the screening pool for
continued surveillance and could offer an opportunity for risk com-
munication. This study has future implications for CRC screening in
the UK as well as contributing to research in risk based screening
and CRC prediction models.
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Introduction Several multidimensional prognostic indices (PI) for COPD
have been developed, mostly based on patients with moderate/severe
COPD. PIs have been developed to predict a range of outcomes includ-
ing mortality, hospitalisations and exacerbations. The Birmingham
COPD Cohort study will examine the performance of these indices in a
primary care COPD population.
Aims & objectives Use preliminary data to determine the predictive
ability of selected PIs in relation to self-reported respiratory hospitali-
sations at 1 and 2 years.
Methods Patients were recruited from 71 general practices in the
West Midlands, UK. Patients either had diagnosed COPD or were
identified through case-finding. Baseline data from 668 participants
were used to calculate 3 PIs (ADO, BODE, DOSE). Discrimination and
calibration of the PIs was examined.
Results According to c statistic estimates, all models had reasonable
discrimination in relation to 1-year respiratory hospitalisations (c; 95%
CI: ADO 0.81; 0.75–0.88, DOSE 0.78; 0.70–0.86, BODE 0.75; 0.67–0.84)
and 2-year respiratory hospitalisations (c; 95% CI: ADO 0.76; 0.69–0.83,
DOSE 0.75; 0.69–0.82, BODE 0.70; 0.62–0.78).
All models had poor calibration for predicting 1-year and 2-year re-
spiratory hospitalisations.
Conclusions All models performed moderately well identifying pa-
tients with respiratory hospitalisations, but were poor at predicting
future events. The data suggest that ADO could be a useful tool for
identifying those at higher risk of respiratory hospitalisations. The
analyses will be repeated on the complete sample once data is avail-
able. Components from existing PIs will be considered alongside can-
didate variables from the Cohort study, to modify or develop a
prognostic index that more accurately predicts events in primary care
COPD patients.
Funding This abstract summarises independent research funded by
the NIHR under its Programme Grants for Applied Research
Programme (Grant Reference Number RP-PG-0109-10061). The views
expressed are those of the authors and not necessarily those of the
NHS, the NIHR or Department of Health. The Birmingham COPD
Cohort study is part of the Birmingham Lung Improvement
StudieS – BLISS.
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The kappa statistic is widely applied to assess the agreement between
two clinicians rating patients on a nominal or ordinal scale. The Gwet’s
coefficient has been proposed as a better alternative.
Three or more raters are often involved in such studies, e.g., 2 junior
and 2 senior clinicians assessing the same patients. The question that
arises is: is the agreement between the 2 junior clinicians equal to
the one between the 2 senior ones. Such pairs of agreement coeffi-
cients (AC) are correlated. The confidence interval (CI) for the differ-
ence (or ratio) between 2 correlated ACs can easily be obtained by
bootstrap. The closer 2 correlated ACs are, the more likely it is that
the CI for their difference (ratio) contains and is ‘centred’ on 0 (1 in
the case of ratio), and the larger the corresponding p-value. How-
ever, a paradox arises in practice as the CI is less likely to include 0
(1 in the case of ratio). This is due to the bootstrap distribution being
truncated. This leads to the CIs being biased, having wrong limits,
being too narrow and not corresponding any more to the p-values.
The truncation is described and explained with real data. A simple
solution is provided to tackle this issue.
The real data includes 2 trained and 2 experienced physicians asses-
sing patients from a prosthetics and orthotics clinic with the Inter-
national Classification of Functioning, Disability and Health (ICF).
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Background: Assays measuring levels of antidrug antibodies in
Crohn’s disease patients treated with anti-TNF agents (e.g. Infliximab)
are becoming increasingly used and may be predictive of a patient’s
treatment response status possibly enabling optimisation of treat-
ment. In most studies test results are dichotomized (+ve and –ve)
and allocated to patients with loss of response (LOR) or response to
treatment, thereby generating a 2 × 2 contingency table of associ-
ation. The four cells of the 2 × 2 table characterise the four possible
associations between the binary test and patient outcome. Published
meta-analyses (MA) of such studies have not adopted a test evalu-
ation perspective. Two differing types of MA have been undertaken:
Lee et al. (2012) and Nanda et al. (2013) pooled relative risk ratios
([a/a + b]/[c/c + d]), where [a/a + b] is equivalent to PPV and [c/c + d]
to “1 – NPV”, and the resulting ratio does not correspond to any
commonly used measure of test accuracy; while Paul et al. (2014)
pooled the odds ratio [a/b] /[ c/d] which rearranges to [a*d / b*c]
and is equivalent to an estimate of the diagnostic odds ratio (DOR).
Neither of these statistical approaches allow for the correlation be-
tween columns in the 2 × 2 table.
Aim: We aimed to compare meta-analytical outputs using the MA ap-
proaches taken by Nanda and Paul with the bivariate random effects
model using studies of assays measuring antibodies to Infliximab to
predict LOR in Crohn’s disease patients to document differences in
MA outcomes and interpretation.
Methods: We used systematic review methods to search for, identify
and quality assess relevant studies. We calculated unadjusted risk
ratios and unadjusted odds ratios and pooled data in Stata using
fixed (Mantel-Haenszel) and random effects (Der Simonian and Laird)
models. We calculated sensitivity and specificity and undertook
hierarchical / bivariate meta-analysis with the user-written “metandi”
package of Harbord and Whiting in Stata. Sensitivity analyses were
undertaken.
Results: We included 20 studies reporting results in 1240 patients
with Crohn’s disease. Studies were considered at high risk of bias in
at least one quality domain. The pooled risk ratio using fixed effects
and random effects models was 2.1 (95% CI 1.8–2.4) and 2.2 (95% CI
1.6–3.2), respectively. This outcome could be interpreted as: the risk
of experiencing LOR in the test positive population (a/a + b) is twice
the risk of experiencing LOR in the test negative population (c/c + d).
The pooled DOR was 4.6 (95% CI 2.5–8.5). This outcome could be
interpreted as: the ratio of the odds of the test being positive if the
patient experiences LOR relative to the odds of the test being
positive if the patient is a responder is 4.6. An odds ratio of 5 would
suggest a very strong association of marker and clinical outcome in
traditional epidemiological studies of association but is uninformative
in terms of the discriminatory power of the marker. Using the bivariate
meta-analysis the pooled summary estimates of sensitivity and specifi-
city were 0.56 (95% CI 0.44–0.67) and 0.79 (95% CI 0.69–0.87), respect-
ively suggesting the assay to be a fair predictor of response at the
most and does not render itself as a tool for treatment decisions. Sensi-
tivity analyses showed different results for different methods.
Conclusion: The meaning of a pooled risk ratio is questionable and
the pooled DOR can be misleading. Neither method is as useful in
evaluating tests as a bivariate model.
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A major contributor to the rising problem of overdiagnosis, with the
subsequent risk of overtreatment, is the development of highly sensi-
tive diagnostic technologies that challenge and sometimes expand
prevailing disease definitions. Although the value of such new tech-
nology might be that it identifies new, milder, earlier or even other
abnormalities, it is uncertain whether these “abnormalities” provide
the same diagnostic and prognostic information, or require the same
treatment as the original targeted disease. It is often unclear which
of the newly detected abnormalities are benign and how many
people might be diagnosed and treated unnecessarily as a result of
widespread introduction of the new test. Failure to investigate the
clinical relevance of broadening disease definitions which include
these newly detected abnormalities may therefore lead to overdiag-
nosis and overtreatment. Spiral CT used in diagnosing pulmonary
embolism, detecting small subsegmental embolisms, has been men-
tioned as an example of such situation.
On-going technological advancements in medicine will only further in-
crease the development of new diagnostic technologies that challenge
existing disease definitions. We show why traditional cross-sectional
diagnostic accuracy studies are insufficient to evaluate such new tests
and how methodology for assessing their performance should catch
up and keep pace with present-day technological developments. It is
crucial to improve data analysis and presentation of current diagnostic
studies, to make better use of existing data, or ultimately perform test-
treatment trials to answer the question whether introduction of a new
high sensitive test will in fact improve patient relevant outcomes, or ra-
ther induce overdiagnosis and overtreatment.
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Background: Coagulopathic bleeding is a common and severe com-
plication of cardiac surgery. Identifying patients likely to bleed may
allow earlier and more targeted therapy and reduce morbidity attrib-
utable to bleeding and transfusion. We aimed to evaluate whether
the results of near-patient haemostasis tests performed before, and
immediately after cardiac surgery improved the prediction of subse-
quent clinical concern about bleeding (CCB).
Methods: Eligible patients were invited to participate in a prospective
cohort study to estimate the predictive value of baseline patient and
procedural characteristics and 28 near-patient platelet and viscoelasto-
metry test results obtained before and after surgery. Eligible partici-
pants were adults having a range of elective or urgent open-heart
surgery procedures at the Bristol Heart Institute between March 2010
and August 2012. The primary outcome CCB is a composite of high
blood loss, re-operation for bleeding that excluded surgical causes or
administration of a pro-haemostatic treatment that was not part of the
standard surgical care protocol. A predictive model that incorporated
the baseline characteristics (such as age, sex, operative urgency and
procedure) was compared with various alternative models that also in-
cluded the 28 pre-operative and post-operative test results. The best
predictive model was selected on the basis of the c-statistic (area under
receiver operating characteristic curve).
Findings: CCB occurred in 449 (24.5%) of 1833 patients. A multivariable
predictive model for CCB based only on baseline demographic and
clinical characteristics had a c-statistic = 0.72; (95% CI 0.69 to 0.75) and
correctly classified 76.8% of patients. Adding the most predictive near-
patient test results before and after surgery to the baseline characteris-
tics model improved the prediction of CCB (c-statistic = 0.75 (0.72 to
0.77)), but increased the proportion of patients correctly classified by
only 0.98% (18 patients). The best predictive model incorporating both
baseline characteristics and near-patient test results correctly reclassi-
fied 63 patients and incorrectly reclassified 45 patients compared to
the model for baseline characteristics only. Both models were internally
validated using bootstrapping and cross-validation techniques; the
baseline model was also externally validated in a separate cohort of
1611 adult cardiac surgery patients (c-statistic = 0.64 (0.60 to 0.67)).
Conclusions: The results from existing near-patient haemostasis blood
tests performed immediately before and after cardiac surgery offer little
improvement in the prediction of CCB compared to baseline patient
characteristics alone.
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Objective: Randomised controlled trials (RCT) are widely regarded as
the gold standard of trial design but remain rare in the evaluation of
diagnostic test strategies. The use of point-of-care testing (POCT) is
increasing and an understanding of the impact to clinical pathways
is required by policy makers to facilitate adoption. This study aimed
to investigate the endpoints used in RCTs to evaluate POCT. Second-
ary aims were to assess study design and quality of included studies.
Study design and setting: An electronic search of EMBASE and Med-
line was performed. Descriptive data of study design was extracted
and a hybrid quality assessment tool used to score included studies.
Results: Eighty-four studies were included evaluating 37 POCT. Five
(6%) studies investigated more than one test. The five most commonly
studied test devices were coagulation (11 studies (13%)), malaria (10
studies (12%)), human immunodeficiency virus antibody (9 studies
(11%)), cardiac enzyme markers (7 studies (8%)) and thromboelastogra-
phy (5 studies (6%)). 76 (90%) of studies had primary endpoints that
reflected patient outcomes with the most frequently observed primary
endpoints being treatment efficacy and therapeutic yield that together
accounted for 43 (51%) of included studies. 14 (17%) of studies investi-
gated resource use as a primary endpoint including cost-effectiveness
(11 studies (13%)), length of stay (3 studies (4%)) and frequency of
doctor-patient interactions (2 studies (2%)). Forty (47%) studies were
multi-centre and 18 (21%) studies were undertaken in World Bank de-
fined developing countries. Five (6%) studies had appropriate blinding;
method of randomization and sample size were not reported in 24
(29%) and 19 (23%) of studies respectively.
Conclusion: There remains controversy as to the importance of RCTs in
diagnostics and to what degree RCT evidence contributes to successful
adoption. This review highlights the scope of endpoints that can be ob-
tained from RCTs that in the main are markers of clinical utility rather
than validity and therefore may provide a better understanding of how
diagnostic tests affect patient and societal outcomes.
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Background: After a prognostic model has been developed it is im-
portant to evaluate its performance in an independent dataset, often
referred as external validation. However, data sets used to evaluate
prognostic models are frequently too small, and the handling of
missing data has been shown to be poor.
Method: Using resampling methods with large real dataset (THIN),
we investigate the impact of the missing data in the validation co-
hort on the evaluation of performance of the QRISK2 model for pre-
dicting the 10-year risk of developing cardiovascular disease. We also
include an examination of the influence of varying the sample size.
Five levels of missingness (varying from 5% to 75%) were imposed
using a missing at random (MAR) mechanism, as well as varying the
sample size (number of events; from 10 to 1000). Four missing data
methods were applied: complete case analysis, multiple imputation
using regression switching, multiple imputation using predictive
mean matching and multiple imputation using flexible additive im-
putation models. The performance of QRISK2 was assessed by calcu-
lating measures of discrimination (c-index, D-statistic) and calibration
(calibration plot). The impact of the four different approaches for
handling the missing data was examined by calculating the percent-
age bias.
Results: When the amount of missing data was small, there was little
difference between the various approaches for handling missing
data. However, as the amount of missing data increased, multiple
imputation methods provided least biased estimates and better per-
formance than the complete case analysis. These findings were also
consistent over all the sample size scenarios examined.
Conclusion: Our study provides insight into the impact and handling
of missing data on model performance. In all scenarios, regardless of
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the sample size, multiple imputation outperformed complete-case ana-
lyses and should be considered when validating a prognostic model
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Background: Publications on multivariable clinical prediction models
have become abundant for both prognostic and diagnostic purposes.
Systematic reviews of these studies are increasingly required to iden-
tify and critically appraise the existing evidence. There is currently no
checklist or tool providing guidance for systematic reviews of studies
developing or validating prediction models that can assist reviewers
to define the review objectives and appraise study methodology.
Objective: To develop a checklist to help reviewers framing a well-
defined review question, and to determine which details to extract and
critically appraise from primary studies on the development or valid-
ation of multivariable diagnostic or prognostic prediction models, with
a view to assessing the risk of bias and sources of heterogeneity.
Methods: We critically examined existing reporting guidelines and
quality assessment tools, key methodological publications on clin-
ical prediction modelling, and tools used in published systematic
reviews of multivariable prediction models, to identify the relevant
characteristics and domains. The checklist was tested in various sys-
tematic reviews.
Results: We identified 7 items important for framing the review ques-
tion (diagnostic versus prognostic model, intended scope of the review,
type of prediction modelling studies, target population, outcome to be
predicted, time span of prediction, intended moment of using the
model), and 11 domains to critically appraise the primary included
studies (source of data, participants, outcome, predictors, sample size,
missing data, model development, model performance, model evalu-
ation, results, interpretation). Both were combined into the CHecklist
for critical Appraisal and data extraction for systematic Reviews of pre-
diction Modelling Studies (CHARMS).
Conclusions: CHARMS is designed to assist reviewers to help system-
atic reviewers framing their review objectives, and to determine
which data to extract and critically appraise from primary studies on
the development and/or validation of (diagnostic and prognostic)
prediction models.
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Background and objective. Patients and care providers are confronted
with making numerous decisions based on a probability; a probability
that a specific disease or condition is present (diagnostic setting) or a
specific event or outcome will occur in the future (prognostic setting).
To guide practitioners and patients in these probability estimations, so-
called multivariable prediction models are developed. Prediction
models convert 2 or more pieces of information, i.e. predictors, from
the participant - e.g., an individual’s age, gender, symptoms, signs,
laboratory and imaging test results - into a diagnostic or prognostic
probability. Prediction models are becoming increasingly abundant. In
virtually all medical domains, prediction models are being developed,
evaluated (validated), extended and implemented. For some specific
diseases, there are even an overwhelming number of competing
prediction models for the same outcome or target population. It is
therefore important that these clinical prediction models and the
research done to develop, evaluate or extend these models be trans-
parently reported. However, the overwhelming evidence shows that
the quality of reporting of prediction model studies is poor. Only with
full and clear reporting of information on all aspects of a prediction
model can risk of bias and potential usefulness of prediction models be
adequately assessed.
Methods and results. The Transparent Reporting of a multivariable
prediction model for Individual Prognosis Or Diagnosis (TRIPOD)
initiative, which has included numerous clinicians, statisticians, epide-
miologists and journal editors, has produced a guideline for the
reporting of studies developing, validating or updating a prediction
model, whether for diagnostic or prognostic purposes. The TRIPOD
Statement is a checklist of 22 items, deemed essential for transparent
reporting of any prediction model study, and addresses model devel-
opment, model validation and model extension studies, regardless of
the study methods used. The TRIPOD Statement is accompanied by
an Explanation and Elaboration article that describes the rationale for
the checklist, clarifies the meaning of each item, and discusses why
transparent reporting is important, with a view to assessing risk of bias
and clinical usefulness of a prediction model. Each item is explained in
detail and accompanied by published examples of good reporting. The
document also provides a valuable reference of issues to consider
when designing, conducting, and analyzing prediction model studies.
Conclusions. The endorsement and use this checklist by researchers
and medical journal editors will help ensure that medical research find-
ings are complete and accurately reported, understood by readers, and
ultimately used by medical practitioners.
P11
Incorporating the time-dependency in ROC methodology for
censored clinical event
Adina Najwa Kamarudin, Ruwanthi Kolamunnage-Dona, Trevor Cox
Department of Biostatistics, University of Liverpool, Liverpool, UK
Correspondence: Adina Najwa Kamarudin (adinajwa@liv.ac.uk)
Diagnostic and Prognostic Research 2016, 1(Suppl 1):P11
The classical approach of ROC (receiver operating characteristic) ana-
lysis considers event (disease) status and biomarker of an individual as
fixed over time; however in practice both the disease status and bio-
marker change over time. Individuals who are disease-free earlier may
develop the disease later due to longer study follow-up, and also have
their biomarker changed from baseline over follow-up. Thus, an ROC as
function of time is more appropriate. The time-dependent sensitivity
and specificity can be defined into three definitions which are cumula-
tive/dynamic (C/D), incident/dynamic (I/D) and incident/static (I/S). We
focus on I/D and I/S definitions in this presentation. Incident sensitivity
and dynamic specificity use a pre-defined time point for discriminating
between individuals who failed and individuals who remained disease-
free while static specificity uses a time interval. Further, I/D definition is
used for a single marker while I/S definition is used for longitudinal
marker. We review the current estimation methods and compare their
behaviour in practice using a real dataset in primary biliary cirrhosis.
Keywords: ROC, time-dependent, accuracy, biomarker, event-time,
longitudinal data
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Over the past few decades, an unprecedented number of medical
devices emerged, including point-of-care tests (POCTs). Convenience
and accessibility support timely clinical decision-making, promoting
better, more efficient care. Despite the potential, however, the use of
POCTs is still limited in the UK. Adoptions are crippled by immediate
and definitive costs but future and uncertain benefits. Bayesian net-
works are graphical tools for dealing with uncertainties. Within BNs,
events are represented by circles and their relationship by arrows.
BNs offer an intuitive way of understanding uncertainties. In this re-
search, we use BNs to map out adoption and evidence generation
process involved in assessing medical technologies. We demonstrate
how BNs can help decision makers understand the roles and stages
of evidence generation, importance of engaging with stakeholders,
achieving effective communications and more efficient allocation of
resources.
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Background: Cardiac surgery-associated acute kidney injury (CSA-AKI)
has received increasing attention over the last years, when new bio-
markers have been discovered and some of them have been broadly
tested. Unfortunately, none has reached the clinical phase and diagno-
sis and classification are still based on serum creatinine (sCr) and diur-
esis. We investigate alternative biomarkers to predict CSA-AKI.
Design: It is a retrospective study of consecutive patients undergoing
major cardiac surgery using a computerized database with prospect-
ively collected data. The total sample was divided in two halves, the
exploratory sample, used to achieve the main objectives and the
validation sample, used to validate the results.
Methods: The ability of the biomarkers to predict AKI in advance was
measured with time-dependent ROC curves. We evaluated if the
results in the validation sample were similar to the results in the
exploratory one. The simplest and most widely used approach to test
equivalence is the two one-sided test (TOST). Equivalence is accepted
when the 90% confidence interval (CI) of mean AUC difference
between the exploratory sample and the validation sample fall within
the acceptance limits (0.8 to 1.25).
Results: An AKI event was developed in 610 out of 1980 (30.7%)
patients, in the exploratory sample. One of the biomarker studied
showed a good performance for AKI prediction, with values for the
area under the ROC curve between 0.70 and 0.94. Similar results
were obtained in the validation sample where equivalence was
accepted in all cases, Fig. 6.
Interpretation: An alternative biomarker to sCr has been obtained to
predict AKI events after cardiac surgery using time-dependent ROC
curves as the statistical tool to measure its performance. The results
in the validation sample are similar to the results in the exploratory
sample then we can be reassured about its accuracy.
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Background: There is an ongoing debate about the harms and benefits
of implementing a national screening programme for prostate cancer.
The screening test (Prostate Specific Antigen, PSA) has poor sensitivity
and specificity, meaning it produces a high proportion of false positive
and false negative results. The PSA screen is followed by a biopsy
which itself has relatively poor sensitivity. The subsequent treatments
for screen and biopsy detected prostate cancer impact significantly on
quality of life and resources.
Men may have screen-detected prostate cancer but the disease may
never develop to cause symptoms within their lifetime. The potential
benefits of screening are for those who have prostate cancer that is
destined to progress because the cancer is identified sooner than in
clinical practice and is treated earlier, potentially improving life expect-
ancy. Men with a false positive PSA test result are, on the other hand,
subjected to unnecessary tests and treatment, whilst the men with a
false negative result (and with prostate cancer that is destined to pro-
gress) may have necessary treatment delayed.
Since the mid-1990s, there have been many model-based economic
evaluations published assessing the cost-effectiveness of screening
for prostate cancer, using a variety of modeling methods that in turn
may impact the results from the model.
Fig. 6 (abstract P13). The 90% CI of mean AUC differences between
the exploratory sample and the validation sample corresponding to
severe AKI. Dotted line are the equivalence margin with Δ = 20%
(wider interval) and Δ = 10% (narrower interval)Fig. 5 (abstract P12). See text for description
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Objective: To summarise existing methods used in decision models
of prostate cancer screening, and to identify key issues and areas for
further methodological development.
Method: Systematic review of modelling studies from electronic data-
bases and grey literature that assess PSA screening for prostate cancer.
The review follows guidance from the Centre for Reviews and Dissem-
ination and is restricted to evidence from the last 10 years to reflect
current practice in screening for prostate cancer and economic evalu-
ation methods. Information is extracted on model type, structure and
calibration, how the natural history of disease has been handled, and
the extent to which uncertainty in the cost-effectiveness result has
been quantified.
Results: 12 modelling studies have been identified to date in settings
across Europe, USA, and Asia. Analysis suggests that model types
range from decision tree to discrete event simulation, different
approaches to model calibration are adopted and the conditional
dependence between the screen and biopsy is rarely mentioned. The
quality of life values used are crucial to the results and are often
taken from outdated studies using a variety of elicitation methods.
Numerous assumptions are made due to the limited availability of
relevant information on disease natural history, and these assumptions
do not include clinical input. The methods for assessing overdiagnosis
are inconsistent.
Discussion: Despite the relatively large number of models, there are
still important issues when modelling prostate cancer screening that
can impact the results and require refinement.
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Background: In recent years, advances in targeted therapies for the
treatment of mCRC have elevated the expectations of biomarker-
guided treatments because a biomarker may improve health outcomes
by delivering the right treatment to the right patient while avoiding an
unnecessary treatment of patients unresponsive to the therapy. How-
ever, the cost-effectiveness (CE) of biomarkers remains unclear. This
study aims to review recent literature on the CE of biomarkers together
with targeted therapies for mCRC.
Method: A literature search was performed using MEDLINE (Ovid)
and National Health Service Economic Evaluation Database (NHSEED).
Cost-effectiveness as well as cost-utility studies were identified. The
study selection was based on the inclusion and exclusion criteria for-
mulated by the framework of PICOS (population, intervention, compar-
ators, outcomes, study types). Publications from 2010 through February
2016 were searched.
Result: Five hundrend sixty-six publications were searched in total, and
twenty-two papers were included in the review. Of these, twenty stud-
ies were model-based analyses including Markov models and area
under curve (AUC) models, and two were trial-based. The number of
strategies compared ranged from two to seven arms per study. Overall,
the CE of targeted therapies with or without biomarkers produced
conflicting results. No studies on bevacizumab, aflibercept and regoraf-
enib considered the use of biomarkers. However, two studies reported
incremental cost-effectiveness ratios (ICERs) on patients with wild-type
Kirsten rat sarcoma (KRAS). As for ramucirumab, no economic evalua-
tions published to date.
Meanwhile, all studies of cetuximab and panitumumab have con-
sidered the use of biomarkers. Overall, the CE results varied de-
pending on different combination of strategy arms consisting of: (a)
no prior biomarker test performed and all patients treated with
intervention, (b) no prior biomarker test performed and all patients
treated with best supportive care(BSC)/chemotherapy, and (c) bio-
marker test performed and treatment guided by the biomarker
result (wild-type KRAS patients receive the intervention and mutant
KRAS patients receive BSC/chemotherapy). Ten studies analysed
cetuximab including seven studies as a monotherapy and six studies as
a combination therapy. For cetuximab strategy (a) was never cost-
effective compared to strategy (b) and (c). However, when strategy (c)
was compared to strategy (b), it revealed conflicting results; two studies
indicated that it was cost-effective, and two that it was not cost-
effective. Six studies were done on panitumumab and they showed
similar patterns of CE results depending on the different combination
of strategies.
Conclusion: Our review found that the choice of comparators is a
key driver in determining the CE of biomarkers in the context of tar-
geted therapies. Strategies that ‘treat all with intervention without
KRAS testing’ were not cost-effective compared to ‘treat all with BSC/
chemotherapy without testing’ strategies. In contrast, ‘treat WT KRAS
only with testing’ is either cost-effective or cost-saving when com-
pared to ‘treat all with intervention without testing’. It was then
shown mixed results when ‘treat with testing’ was compared with
‘treat all with BSC/chemotherapy without testing’. Whether or not
use of biomarkers to inform the treatment decision is cost-effective
is largely driven by the expected impact on health outcomes.
P16
Review strategies to inform research prioritization of biomarkers:
AKI-Diagnostics case study
Elizabeth Mitchell1, Alison Smith1, Judy Wright1, Peter Hall3,
Michael Messenger2, Nicola Calder4, Nyantara Wickramasekera1,
Karen Vinall-Collier5, Andrew Lewington2
1Leeds Institute of Health Sciences, University of Leeds, Leeds, UK; 2NIHR
Diagnostic Evidence Co-Operative Leeds , Leeds Institute of Health
Sciences, University of Leeds, Leeds, UK; 3The Institute of Genetics and
Molecular Medicine, Edinburgh Cancer Research Centre, University of
Edinburgh, Edinburgh, UK; 4Leeds Teaching Hospitals NHS Trust, St
James’s University Hospital, Leeds, UK; 5School of Dentistry, University of
Leeds, Leeds, UK
Correspondence: Judy Wright (J.M.Wright@leeds.ac.uk)
Diagnostic and Prognostic Research 2016, 1(Suppl 1):P16
Background: Numerous biomarkers for the early diagnosis and moni-
toring of Acute Kidney Injury (AKI) have recently been developed.
Evidence on their clinical validity and utility is variable, and there is a
time-limited opportunity to propose an efficient future research
strategy for AKI diagnostics in the UK, to inform optimal test-
reimbursement decisions. The ongoing NIHR AKI-Diagnostics study
aims to inform future research by conducting a systematic review
and early economic evaluation of biomarkers for AKI in the critical
care setting.
Methods: A two-stage search process was adopted. Stage 1 consisted
of a broad scoping search of world literature to identify candidate
biomarkers for evaluation. The results were used to produce a ranked
shortlist of priority biomarkers according to criteria agreed via expert
consensus: volume and currency of evidence, number of samples
studied, and biological plausibility. Stage 2 (underway) consists of a
systematic review to identify evidence on the analytical and clinical
validity, and clinical utility of the priority biomarkers.
Results: The scoping search identified 4,804 references. After screen-
ing by titles/abstract, 487 potentially relevant papers remained, re-
lating to 152 individual biomarkers. Those already used in standard
care (11; including serum creatinine) or with incomplete data re-
lated to the dimensions outlined above (19) were excluded. Ten pri-
ority biomarkers/tests were shortlisted: BNP, Cystatin C, IL-6, IL-18,
KIM-1, L-FABP, NAG, Nephrocheck©, NGAL and TNF-α. The subse-
quent systematic review has identified 5,071 citations. Data extrac-
tion to date has focused on the top 3 tests: Nephrocheck© (which
has received significant marketing and is the only FDA licensed
test), Cystatin C and NGAL (both with the greatest volume of evi-
dence). Currently, 110 papers have been included: 6 Nephrocheck©,
48 Cystatin C, 56 NGAL.
Reflections: Several key issues were encountered in the review. First,
in the absence of published guidance, the test shortlisting criteria
were developed by expert consultation, and may not capture promis-
ing in-development tests due to the pragmatic focus on objective
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criteria (e.g. volume of evidence). Second, the volume of evidence
was substantially greater than originally indicated by pre-study scop-
ing searches, largely due to the decision to broaden the final scope
to include tests developed outside the critical care setting. Together
with the number of candidate tests identified (including multiple
tests used in conjunction) and the complexity of data extraction in-
volved, this resulted in extended study timelines. Finally, poor report-
ing, especially of analytical factors, makes comprehensive synthesis
of test analytical and clinical validity difficult.
Conclusion: As the number of biomarkers entering the healthcare
market continues to rapidly expand, the role of reviews to inform
future research priorities is becoming increasingly important. The
two-stage search process outlined here represents a novel approach
in this area; however, it is clear that further work is required to estab-
lish efficient and optimal search strategies and shortlisting criteria for
such reviews.
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Background Prognostic models are often designed to estimate an
individual’s future risk of disease given that they are not receiving
a certain treatment and will remain untreated. In practice, individ-
uals enrolled in studies that aim to develop or validate such
models may receive treatment to prevent the outcome of interest
during the study. This can lead to an underestimation of the true
untreated risk in those who were treated, which may impact upon
the accuracy or validity of newly derived models, or may bias the
findings of a validation study. It is not yet clear how and to what
extent treatment use is being addressed in prognostic modelling
studies.
Objectives To provide insight into the degree to which relevant treat-
ment information is reported and handled in the derivation and valid-
ation of prognostic models, and what impact this may have, using the
field of cardiovascular risk prediction as an example.
Methods For the current study, we made use of a previously con-
ducted systematic review (search: June 2013) to identify articles
that reported prognostic models in the field of cardiovascular pre-
ventative medicine, in a general population setting. Data were col-
lected on the reporting of treatments (blood pressure, lipid and
other medications, surgical procedures and lifestyle modifications),
including the frequency and timing of treatment use, how treat-
ments were handled in the analysis, and any discussion regarding
the implications of treatment use.
Results The search strategy yielded 9965 unique titles, of which 302
articles were included for the current analysis.
Of these articles, 91 (30%) did not mention treatments with respect
to the characteristics of study participants, prediction modelling, or
their relevance to the findings of the study. 146 articles (48%)
reported specific information about treatment use at study entry; 78
articles (26%) provided information about more than one treatment.
Information about changes in medication use during follow-up was
rare (1%). Treatment effects were accounted for in 79 articles (26%)
by including only individuals without a certain treatment in the ana-
lysis. Of all the articles that developed a model, 80 included treat-
ment use at baseline as a predictor; changes in treatment during
follow-up were not modelled. Possible implications of treatment use
with respect to model performance or applicability were discussed in
only 24 articles (8%).
Conclusions This review finds that treatment use has largely not been
addressed in cardiovascular prognostic modelling studies. The absence
of treatment information in reporting may lead to difficulties when
validating or implementing a prognostic model, and may lead to
uncertainty over whether a model will provide correct risk estimates
when used in practice. Greater consideration is needed when collect-
ing, reporting and handling treatment information.
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n Vitro Diagnostic (IVD) medical devices form the basis of ~70% of
clinical decision making in the NHS. The accuracy and associated
uncertainty surrounding diagnostic testing consequently has a
major impact on the overall quality of clinical decisions and subse-
quent clinical and cost effectiveness. Numerous pre-analytical, ana-
lytical and biological factors can contribute to the measurement
uncertainty in diagnostic testing proceedures. These uncertainties
accumulate through the measurement system and may introduce
bias into clinical trials; contribute towards heterogeneity between
biomarker research studies; and limit the applicability of research
findings to clinical practice. Whilst prior reports have highlighted
the scale and impact of these issues and reporting guidelines have
been published (e.g. BRISQ, PROBE-ME), we are not aware of any
methods in use for evaluating the quality and appropriateness of
measurement procedures within systematic reviews of IVDs. We
suggest that this is limiting the ability of systematic reviewers and
health technology assessors to fully evaluate risk and model uncer-
tainty within assessments. This has been highlighted in several re-
cent NICE diagnostic assessment programme reports.
As part of an NIHR funded “Multi-Centre Programme into the Evalu-
ation of Biomarkers Suitable for Use in Patients with Kidney and
Liver Diseases” and an NIHR funded health technology assessment
“AKI-Diagnostics” key parameters for consideration by systematic
reviewers were identified (Fig. 7) and an initial framework for asses-
sing the quality of measurement procedures developed. Pilot evi-
dence from early testing of this template will be presented and has
proved useful in highlighting inadequacies in the reporting and
conduct of measurement procedures that may introduce bias, irre-
producibility or inapplicability. However, further work is required to
refine the parameters and signaling questions for inclusion within
the framework, develop guidance for users and validate its utility
more widely.
Fig. 7 (abstract P19). Feather diagram depicting factors that may
contribute to measurement uncertainty (UM)
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Background: Biopsy is a golden standard for diagnosis of acute
rejection in kidney transplantation, but is associated with risks
and is conducted when graft dysfunction is manifest and graft
damage has occurred. Therefore, there is a need of a non-
invasive method for early identification of rejection prior to graft
damage.
Samples: Five hundrend seventy-three whole-blood samples
were collected at intervals post transplantation from 69 kidney
transplant recipients (KTR), part of the cohort KALIBRE study
(Kidney Allograft Immune Biomarkers of Rejection Episodes). 23
KTRs had experienced biopsy-proven acute cellular rejection at a me-
dian time post transplantation 110 days (min-max 6–364 days) and 46
KTRs had stable kidney function with serum creatinine within 15% from
a baseline and no clinical signs of graft failure for the first post-
transplant year.
Methods: RT-qPCR expression was examined for 22 literature-
based genes, including the Allomap signature of heart transplant
acute rejection (1), as well as Granzyme B, Perforin, Fas-Ligand,
FoxP3, IP-10, IL-15, TGFβ, CXCR3, NGAL, INFγ and RORc. Time-
adjusted residuals were generated from gene expression data
using linear mixed-effects models fitted to samples from stable
patients, accounting for changes unrelated to rejection. A gene
signature was selected based on penalised Cox regression using
as time-independent covariates the time-adjusted residuals for a
sample prior to and nearest to rejection for rejectors or the mean
of all samples for each stable patient. Longitudinal data were
used as a test set.
Results: For the timepoint close to rejection: eGFR alone
showed AUC 0.90 (95% confidence interval 0.83–0.97); the Allo-
map gene set showed AUC 0.76 (0.62–0.89); the full model with
22 genes showed AUC 0.87 (0.78–0.96); a newly-selected 5-gene
signature, containing two Allomap genes, showed comparable
performance to the 22-gene set and eGFR: AUC 0.87 (0.77–
0.96). A cut-off of 0.48 for the log hazard ratio (logHR) relative
to an average patient would provide sensitivity 0.87, specificity
0.80, PPV 0.69 and NPV 0.93, similar to eGFR with cut-off
50.4 ml/min/1.73 m2 (sensitivity 0.83, specificity 0.78, PPV 0.66,
NPV 0.90). However, taking into account the longitudinal
follow-up of logHR predictions from a Cox model with time-
independent co-variates for the 5-gene signature, rejections
could be indicated approximately two weeks earlier compared
to eGFR (see Fig. 8).
Conclusion: Molecular markers of rejection in blood emerge well
ahead of the time of clinically presented acute rejection. Monitoring
of gene expression signatures for early detection of acute rejection is
promising.
Reference
(1) Deng MC et al. Am J Transplant 2006; 6(1):150–60
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Background: The implementation of the Framingham risk models
and Pooled Cohort Equations (PCE) is currently recommended in the
United States for predicting ten-year risk of developing cardiovascu-
lar disease (CVD) in individuals. Over the past few years, these predic-
tion models have been extensively validated in other individuals,
settings and countries.
Objectives: To systematically review and summarize the discrimin-
ation and calibration of three CVD prediction models, and to de-
termine heterogeneity in this performance across subpopulations
or geographical regions.
Methods: In December 2015, Medline and Embase were searched
for studies investigating the external validation of three CVD risk
equations (Framingham Wilson 1998, Framingham ATP III 2002
guideline and PCE 2013). This search was combined with a
search in Web of Science and Scopus for citations of these three
articles. Studies published before June 2013 were identified from
a previous review in which we mapped all CVD risk prediction
models until that date. Studies were eligible for inclusion if they
externally validated the original prediction model without updat-
ing, in a general population setting. Critical appraisal was performed
based on the CHARMS checklist. Data were extracted on participant
selection, case-mix, essential study design characteristics, and model
performance (quantified by the c-statistic and observed/expected ratio).
Performance estimates were summarized using random effects meta-
analysis models that accounted for differences in case-mix to explore
sources of heterogeneity.
Results: The search identified 10,687 references, of which 1,501
were screened in full text and 45 met our eligibility criteria.
Fig. 8 (abstract P20). See text for description
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These articles described the external validation of Framingham
Wilson (25 articles), Framingham ATP III (15 articles) or the PCE
(10 articles). Our meta-analytical results will be presented during
the MEMTAB symposium as we are currently meta-analyzing the
results. We will present the overall range of performance of the
three risk equations and attempt to compare these to each other.
Furthermore, we will present the range of performance for case-
mix differences such as age, comorbidities and treatment.
Conclusion: The results of this study can help in identifying which
of these three CVD models can reliably be used, whether there is
heterogeneity in their performance and whether there are sub-
populations for which further research is necessary to improve
CVD risk prediction.
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Background: Cardiovascular disease (CVD) is a leading cause of
morbidity and the leading cause of mortality worldwide. Many
prediction models have been developed to assess individual CVD risk
to allow targeting of preventive treatment.
Objectives: To provide an overview of all prognostic models that predict
future risk of CVD in the general population, and to describe their report-
ing on predicted outcomes, study populations, predictors, and methods.
Methods: In June 2013 a systematic search was performed in Medline
and Embase to identify studies that described the development or ex-
ternal validation of a model predicting CVD in the general population.
Results: Nine thousand nine hundred sixty-five references were identi-
fied, of which 1388 were screened in full text. 212 articles were in-
cluded in the review, describing the development of 363 prediction
models and 473 external validations. Most models were developed in
Europe (n = 167, 46%), predicted risk of coronary heart disease (n = 118,
33%), over a 10-year period (n = 209, 58%). The most common pre-
dictors were smoking (n = 325, 90%) and age (n = 321, 88%), and the
majority of models was sex-specific (n = 250, 69%). Substantial hetero-
geneity in predictor and outcome definitions was observed between
models and important clinical and methodological information was
often missing. For 49 models (13%) the prediction time horizon was
not specified and for 92 (25%) crucial information was missing to actu-
ally use the model for individual risk prediction. Only 132 developed
models (36%) were externally validated and only 70 (19%) by inde-
pendent investigators. Model performance was very heterogeneous
and measures such as discrimination and calibration were reported for
65% and 58% of the external validations respectively.
Conclusion: There is an excess of models predicting incident CVD in
the general population. The usefulness of the majority of the
models remains unclear due to methodological shortcomings, in-
complete presentation, and lack of external validation and model
impact studies. Rather than developing yet another similar CVD risk
prediction model, future research should focus on externally valid-
ating and head-to-head comparisons of the promising existing CVD
risk models, on tailoring these models to local settings or even
combining them, and investigating whether they can be extended
by addition of new predictors.
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Background: Meta-epidemiological studies have shown that study results
are directly influenced by study design characteristics. The results of a ran-
domized trial may for example be biased by inadequate allocation
concealment, lack of blinding of outcome assessments, exclusion of partic-
ipants (e.g. due to selective loss to follow-up) and reporting of intermedi-
ate outcomes. The diagnostic accuracy of tests may be overestimated in
case-control studies, and the choice of reference standards can lead to
biased study results. Meta-epidemiological studies assessing the influence
of design features on the results of prognostic research are yet missing.
Objectives: To determine which design characteristics of a study influ-
ence the performance of a prognostic model upon external validation,
taking the validations of three established risk prediction models for
cardiovascular disease (CVD) as an example.
Methods: In December 2015, Medline and Embase were searched for
articles investigating the external validation of three CVD risk equations
(Framingham Wilson 1998, Framingham ATP III 2002 guideline and
Pooled Cohort Equations (PCE) 2013). This search was combined with a
search in Web of Science and Scopus for citations of these three arti-
cles. Studies published before June 2013 were identified from a previ-
ous review in which we mapped all CVD risk prediction models until
that date. Studies were eligible for inclusion if they externally validated
the original prediction model without updating, in a general population
setting. Data were extracted on essential study design characteristics.
By conducting a random effects meta-regression of model performance
statistics (c-statistic and observed/expected ratio), we will determine
which study characteristics influence model performance statistics.
Results: The search identified 10,687 references, of which 1,501 were
screened in full text and 45 met our eligibility criteria. These articles
described the external validation of Framingham Wilson (25 articles),
Framingham ATP III (15 articles) and the PCE (10 articles). Our meta-
analytical results will be presented during the MEMTAB symposium as
we are currently meta-analyzing the results. We will present the range
of performance for the three prediction models for different design
characteristics, including study design (e.g. cohort, case control), median
follow-up time, total sample size, assessment of predictors and out-
comes, and handling of missing data.
Conclusion: This study will identify design characteristics influencing
the performance of CVD risk prediction models in external validation
studies. This information will help when interpreting the potential im-
pact of validation studies with certain design flaws, and thereby facili-
tate risk of bias assessment in systematic reviews of prognostic studies.
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Background: Clinical prediction models are increasingly made avail-
able on the Internet or as applications for smart phones. These
models are available for use to both clinicians and the general public.
However, the evidence of whether the model should be used is often
unclear.
Aim: The aim of this study was to review the availability of clinical
prediction models as calculators on the Internet and identify the evi-
dence base on the performance of the model. We also provide some
guidance on principles to follow when preparing a prediction model
calculator to be made available on the Internet.
Methods: In March 2015, the Google search engine was used with a
combination of fifteen search terms that described the concepts of
prediction and calculator. For each search term, the first 50 hits (total
750 websites) were recorded. Websites that presented an online
clinical prediction model that required manual entry of patient level
information that produced a probability or risk of having an undiag-
nosed condition (diagnostic) or a probability or risk of developing a
health condition in the future (prognostic), were eligible. Information
such as the background of the model (e.g. country), intended patient
population, intended user of the model (clinician or patient), informa-
tion on how the prediction models were developed and any details
about their validation model, and finally information on how the
web-calculators are presented (graphical, text, lay terminology) and
to be used were extracted using a pilot-tested extraction form.
Results: A total of 116 models were included; only less than half of
the websites cited references to the articles describing the develop-
ment of model and only 8 websites cited references for the valid-
ation of the model on the website. Most of the prediction models
are poorly documented on the Internet, with little information to
help users actually use them. In many instances, it was unclear on
who the prediction calculator was intended for (with only 44 mention-
ing the target group), less than 20% of websites provided help to use
the model (including frequently asked questions). Only 25 models re-
ported the description for each risk factors, nearly half of the models
(n = 56) presented no information or checks on the ranges of any con-
tinuous factors. Furthermore, many calculators (n = 33) did not display
warning messages when information is entered incorrectly.
Conclusion: Prediction models are widely available on the Internet to
support decision-making for clinicians and general public, yet the in-
formation presented alongside the models is inadequate, should be
used with care.
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Background: Diagnosis of infection in the elderly primary care popu-
lation is a clinical challenge, and point of care CRP testing could offer
diagnostic benefit. However, GPs have expressed doubts over the
value of CRP in the context of an aging immune system. The use of
C-reactive protein (CRP) as a reliable marker of severe infection in
the elderly undifferentiated primary care population has not been
sufficiently validated, and the relationship between elevated CRP and
neutrophils, another blood marker of infection, has not been well
characterised.
Objectives: To examine 1) the proportion of the elderly primary care
population on whom CRP is measured currently; 2) the distributions
of CRP and neutrophils in blood tests taken in primary care settings;
3) whether correlation and categorization agreement exist between
these tests and whether this varies with increasing age; 4) whether a
change from baseline CRP is demonstrated in the elderly by examin-
ing how CRP varies over short time periods in the same patient.
Data: Routinely collected, anonymised and de-identified data was ob-
tained from the main laboratory for Oxford University Hospital NHS
Trust. A database was created of all adults who had a blood count
taken in primary care within Oxfordshire CCG during 2012 and 2013
(161,225 patients). The database was then populated with the avail-
able blood test results for those individuals during that period
(478,697 tests).
Methods: Individuals with greater than 12 blood tests in the data-
base were excluded to remove those patients undergoing frequent
monitoring for chronic disease. Analysis was undertaken on the
remaining database (416,989 tests from 158,097 patients). The results
for CRP and neutrophils were categorised as abnormal according to
laboratory reference ranges (CRP: >5 mg/L, neutrophils >7 × 109/L).
Results: Overall, 29% of the target population (registered patients in
Oxfordshire) appear in the database, although this varies with age
(54% of 85-89 year olds, compared with 25% of under 65 s). 34% of
CRP tests were classed as elevated, compared with 10% of neutrophil
tests. The proportions of elevated tests increased with age over
65 years old, for example from 37% of CRP tests elevated in 65-69
year olds to 61% in 95-99 year olds. The majority of tests with CRP
<50 mg/L displayed neutrophil values <7 × 109/L. For CRP >50 mg/L,
approximately half of the corresponding neutrophil tests were not
elevated. Little variation in correlation or agreement was observed
with age. In patients with a sequence of CRP tests each within 7 days
of the previous test, the CRP values were significantly lower on the
second test compared to the first (p <0.001), for both under and over
65 year olds.
Conclusions: In a large dataset of blood tests taken in primary care,
elevated CRP was evident even at the extremes of age, and varied
over short time periods. This suggests that it may have potential as a
diagnostic marker of acute infection or inflammation even at the
extremes of age. Poor correlation between elevated CRP and neutro-
phils was evident across all age ranges and suggests that CRP can be
elevated in the absence of a neutrophilia. A high proportion of the
Oxfordshire elderly population had a CRP blood test performed in
the two year period of our dataset, suggesting that clinicians do at-
tach importance to this marker. Further work is required to evaluate
these findings in a clinical cohort.
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Background: In developing new diagnostic tests and assessing their
benefit for patients, enrichment designs are one popular design. In
enrichment designs, only the test positive patients are randomized
to the two treatments of interest, typically the standard treatment
currently given to all patients and a new treatment expected to im-
prove patient outcomes in test positive patients. Consequently, we
can only conclude that the new treatment is beneficial for test posi-
tive patients. It may happen that other studies randomizing (also)
test negative patients demonstrate (later) that also the test negative
patients benefit from the new treatment. Then there is actually no
need for the test: We can improve patient outcomes just by giving
the new treatment to all patients. Then we can say that the test has
no value. Regulatory and HTA agencies have commented in different
manners on the question to which degree results from enrichment
studies can be used to justify to bring a test into use.
Objective: The different attitudes can be seen as decisions between
a value based and a benefit based strategy. In a value based strategy,
a test is introduced when the value is proven, and in a benefit based
strategy, a test is introduced when the benefit is proven, but later
the decision may be changed and the new therapy may be intro-
duced to all patients. We investigate the potential conclusions form
enrichment designs and interactions designs about value or benefit.
We further investigate the main determinants for the superiority of
one strategy over the other by considering 6 different consequences
for a single test.
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Results: Enrichment designs can inform the benefit based strategy
and interaction designs or separate studies in test positive and test
negative patients can inform the value based strategy. We have to
expect that interaction studies are underpowered to come to a defin-
ite conclusion about the value of a test. Advantages and disadvan-
tages from the strategies are mainly determined by the influence of
the strategies on the timing of performing corresponding studies:
The benefit based strategy allows test positive patients to benefit
earlier from the new therapy, but the strategy may delay the conduct
of interaction studies and hence delay the detection of tests with no
value, but with a benefit from the new therapy for all patients.
Conclusions: Benefit based strategies are preferable if the risk of off
label use and delayed decisions on the value of a test can be limited.
If this cannot be achieved by administrative means like conditional
approval, the superiority of the two approaches depends on how
often the value based strategy would never allow a test of value to
come into use and on how often the benefit based strategy may pre-
vent to detect the no-value status of a test.
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Objectives: In this systematic review we assessed the predictive value
of interim 18F-fluoro-2-deoxy-D-glucose positron emission computed
tomography (FDG-PET/CT) on progression free survival (PFS), event free
survival (EFS), and overall survival (OS) in patients with diffuse large B-
cell lymphoma (DLBCL) treated with first-line chemotherapy regimens.
Studies were designed as prognostic/predictive studies and/or as
diagnostic studies. We present the challenge in searching, scoring and
outcome presentation of this mix of studies and analyses.
Methods
Search and inclusion criteria
We performed a search in three databases (Medline, Embase, Cochrane)
with languages restricted to English, French, German or Dutch. Search
terms consisted of various descriptions of FDG-PET/CT and non-
Hodgkin lymphoma. We included full-text publications of original pro-
spective and retrospective studies in which adult DLBCL patients (>10)
with first-line treatment for DLBCL received an interim FDG-PET/CT be-
tween the first and fifth cycle of chemotherapy. Treatment regimens
were not changed based on the outcome of the interim FDG-PET/CT.
Data on PFS, EFS, OS and/or diagnostic value of interim FDG-PET/CT
were required, with a median follow-up period of at least 24 months.
Prognostic and diagnostic parameters for several types of outcome
measures
Prognostic studies present Kaplan Meier data and/or hazard ratio’s with
PFS, EFS and/or OS as clinical outcome. Diagnostic studies present pa-
rameters such as sensitivity, specificity, negative predictive value (NPV)
and/or positive predictive value (PPV) using PFS, EFS, OS or the end-of-
treatment FDG-PET/CT as reference standard. Primary endpoint is PFS,
as this outcome is of greatest clinical interest when performing an in-
terim FDG-PET/CT. OS and EFS are considered secondary outcomes.
QUADAS-2, PROBAST and the CHARMS checklist were used to assess
the methodological quality and all prognostic and diagnostic data.
Results: We found 47 eligible studies by screening inclusion criteria,
title and abstract. Of this selection, 22 studies presented both prog-
nostic and diagnostic results. Twenty-two studies reported only prog-
nostic results, and three studies reported only diagnostic results.
Discussion: Focus of the presentation will be on the integration of
the prognostic and diagnostic results.
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Background: In the UK, there is a lack of agreement between leading
organizations on which tests should be used for dementia identification
in primary care. The accuracy of many of the commonly-used brief cog-
nitive assessments for dementia is imperfect, and guidelines for diagno-
sis lack consistent direction for health care professionals, policy makers
and the public.
Objectives: To conduct an overview of existing systematic reviews
summarizing the accuracy of brief cognitive assessments for identifying
dementia, particularly for use in primary care.
Methods: We searched EMBASE, MEDLINE, PsychInfo and the Cochrane
Database of Systematic Reviews from inception to 2015. We assessed
the quality of included reviews using the Assessment of Multiple
Systematic Reviews (AMSTAR) measurement tool and the risk of bias in
systematic reviews tool ROBIS. Results were presented narratively with
detailed tables summarizing key data.
Main results: We identified 13 reviews which included a number of dif-
ferent brief cognitive assessments for identifying dementia in primary
care at a range of different thresholds. Included reviews assessed the
diagnostic accuracy of 56 different assessments.
Based on diagnostic test accuracy findings, we summarize the exist-
ing systematic review evidence, comment on the quality of evidence
and make recommendations for research and clinical practice.
Authors’ conclusions: This overview has shown that the breadth of
diagnostic test accuracy evidence is mixed, and there is not one brief
cognitive assessment that clearly emerges as superior to others in
terms of test accuracy.
A number of methodological challenges present themselves within this
overview. The value of conducting an overview review of diagnostic
test accuracy is still debated, and we discuss both our initial aims and
how these match against our overview findings. We encountered a
number of issues of quality and consistency across the evidence base,
and within this presentation we will consider applicability of the evi-
dence and how generalizable this may be to the primary care popula-
tion of interest.
Finally, we will discuss the different purposes of an overview of sys-
tematic reviews of diagnostic test accuracy, and reflect on what other
research methods may be helpful to address these objectives.
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Background: The term “care pathway” refers to the journey a patient
takes during an episode of healthcare.
Care pathway analysis is the comparison between the current path-
way and the proposed pathway if the new test is introduced. It can
involve extensive discussions with clinicians, laboratory managers,
budget holders, patients and all the relevant stakeholders for that
care pathway. Care pathway analyses are often visual representations
or computer models.
The role of care pathway analysis in evaluating clinical tests: Care
pathways are used to map the key management decision points and
processes in a clinical scenario. This is used in the evaluation of clinical
tests to understand the place(s) and purpose(s) of a diagnostic test,
and therefore how it could be an improvement over current practice.
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The potential value of the test (i.e. potential benefits to patients, the
NHS, and budget holders) is easier to identify through care pathway
analysis. Additionally, potential barriers to adoption can become evi-
dent during discussion with stakeholders, and care pathway analysis
can support the design of studies to generate the evidence required to
transform the value propositions of the test, from potential to actual.
Typically, care pathways in a specific disease area vary across differ-
ent healthcare providers and different clinicians. Evaluation of this
variation can be a valuable tool to guide a company’s business plan
and marketing strategy.
Workflows and information flows: Other important pathways to take
into consideration when evaluating a new test are the workflows, and
information flows. These are taken into account using human factors
studies, and service evaluation, for example, to identify who makes the
decision to test, who carries out the test, how the results are communi-
cated to the patient, the relevant clinical stakeholders, and the patient’s
medical records, and finally, how the result is acted upon.
Mapping a care pathway: It is advisable to start mapping the care
pathway, the workflows and the information flows, as early as possible
in the journey from invention to adoption of a new test. Engaging with,
and discussing the care pathway with, the correct stakeholders helps to
identify strengths and weaknesses of the new test; clarifying its role
and place within the current healthcare system.
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Background. The NIHR Diagnostic Evidence Co-operative (DEC) Newcas-
tle works closely with industry and academia to help them generate high
quality, robust scientific evidence on diagnostic accuracy, clinical utility
and cost-effectiveness of IVDs they would like be adopted by the NHS.
Problem. There is a lack of clarity among IVD developers (commercial
and academic) of the evidence required for adoption into the NHS.
Innovation. To help IVD developers identify the key value propositions
that will determine adoption of their product, the DEC has developed a
framework for describing an IVD evidence development pathway (see
Fig. 9 below).
Process modelling of care pathways, information flows, and work flows
can be used at an early stage of product development to describe the
product’s key value propositions, and these define the research strategy
needed to provide the supporting evidence.
Experience with putting the framework into practice. We will present
case studies where the framework for articulating the evidence de-
velopment pathway has helped industry draft evidence development
strategy, which is sequenced and stage-gated for cost and capital
efficiency.
We have developed guidelines for IVD developers on the practical ap-
plication of the evidence development framework, and report on how
it may be used to help IVD developers to understand where their prod-
uct sits in the landscape of evidence generation and their next steps in
demonstrating patient benefit, value for money and affordability.
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The National Institute for Health Research (NIHR) Diagnostic Evi-
dence Co-operative (DEC) Newcastle was established in 2013 with
the remit of helping to generate evidence on the clinical utility,
cost-effectiveness, and care pathway benefits of in vitro diagnostic
devices (IVDs). The NIHR DEC Newcastle works collaboratively with
experts from across the National Health Service NHS, academia, and
industry, and has very strong links with patient research support
groups in the North East of England. Our management group in-
cludes representation from the National Institute for Health and
Care Excellence (NICE) to help ensure that evidence generated is
relevant to the NICE assessment programmes, and suitable for
market-oriented adoption. This collaborative approach has the po-
tential to lead to improvements in healthcare services and the qual-
ity of life of NHS patients, by providing patients with access to the
most appropriate diagnostic technologies more quickly, and by
helping the NHS make best use of its resources.
The NIHR DEC Newcastle has successfully collaborated with a num-
ber of companies to help design studies and collect robust, high
quality scientific evidence to support the adoption of their IVDs
into the NHS. Presented examples include: (i) a clinical perform-
ance and budget impact analysis of Alere i Influenza A & B near
patient test, (ii) an Academic Health Science Network funded pro-
ject to validate a regional model of Familial Hypercholesterolemia
diagnosis and cascade testing, and (iii) a clinical performance and
budget impact analysis of Thermo Fisher Scientific’s MR-proADM
for disposition planning of acutely ill patients admitted to medical
admissions units.
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Objectives: To use eye tracking to assess the effect of expected ab-
normality prevalence on visual search and decision-making during
identification of colon polyps using CT Colonography (CTC).
Background: In clinical practice radiologists interpret images in sce-
narios with different expectations of disease prevalence, including
both symptomatic patients and asymptomatic/screening patients.
Previous research on the effect of experimentally varying prevalence
have identified “rare target” effects, where at lower prevalence there
are increases in target conditions missed. Previous eye tracking stud-
ies on interpretation of chest radiographs (single 2D image per pa-
tient) have shown no difference in accuracy but increased length of
image scrutiny associated with increased prevalence expectations.
Most research in radiological imaging includes enrichment for im-
ages with target condition, to allow feasible and timely design of
multi-reader studies. Understanding of the potential effects of preva-
lence on radiologist interpretations amongst other sources of bias is
Fig. 9 (abstract P33). See text for description
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important when applying results of prevalence enriched studies in
clinical practice.
Methods: Thirteen radiologists interpreted endoluminal CTC 3D video
fly-throughs of the same group of ten patient cases, three times each
but in different random orders for each read. Abnormality prevalence
was fixed (50%) but readers were told, before viewing each group, that
prevalence was either 20%, 50% or 80% in the population from which
cases were drawn. Infra-red eye tracking (Tobii X50 or X120) was used
to record reader visual search during each 30 sec video clip. Readers
indicated seeing a polyp by clicking a mouse. Multilevel modelling
quantified the effect of expected prevalence on outcomes using pre-
specified visual search metrics (1).
Results: Differences between reader visual search metrics at expected
prevalences were not statistically significant for time to first pursuit of
the polyp (median 0.5 s, each prevalence), pursuit rate when no polyp
was on-screen (median 2.7 s-1, each prevalence) or number of mouse
clicks (mean 0.75/video (20% prevalence), 0.93 (50%), 0.97 (80%)). There
was weak evidence of increased tendency to look outside the central
screen area at 80% prevalence, and reduction in positive polyp identifi-
cations at 20% prevalence.
Conclusions: This study did not find a large effect of prevalence infor-
mation on most visual search metrics or polyp identification in CTC.
Further research is required to quantify effects at lower prevalences
and in relation to secondary outcome measures.
Reference
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Background and aim: Every year, thousands of articles are published
on prognostic tumour markers often with contradictory results. In
2005, the REMARK guideline for reporting prognostic tumour marker
studies was published. For convenience, a check list covering 20
items was provided. A review of tumor marker studies published in
2006-7 demonstrated that many lacked key information needed by
readers to evaluate their reliability and clinical applicability [1]. The
aim of the current study was to examine whether the quality of
reporting has improved in the meantime.
Methods: As closely as possible, we used the methods of the earlier
review of published articles from the ‘pre-REMARK’ era. This approach
includes the utilization of the same data extraction form with ques-
tions representing subitems of the original items of the REMARK
check list [1]. The literature search for prognostic tumour marker
studies was done in Web of Science in 2013. Altogether, we assessed
adherence to REMARK for 53 publications (2007 to 12) citing REMARK
(‘citing group’) and 53 publications not citing REMARK (‘not-citing
group’; matched by journal and issue). Descriptive comparisons over
time and between groups were done with a particular focus on 10
items of the REMARK check list. Background and reasons for the re-
striction to 10 out of 20 items will be provided.
Results: Overall, the proportion of the 10 key items that were assessed
slightly increased on average from 53% (range: 10% to 90%) in the earl-
ier study to 58% (range: 30% to 100%) in the citing group and to 58%
(range: 20% to 100%) in the not-citing group.
The improvement, however, was not seen in all 10 items. While an im-
provement was substantial for some (e.g. item 6: ‘Study design - follow
up’; past study: 40%, citing group: 60%, not-citing group: 62%), it got
worse for others (e.g. item 13: distribution of demographic characteris-
tics; past study: 58%, citing group: 42%, not-citing group: 55%).
Conclusions: In principle, it should be easy to report all study details
included in the REMARK checklist. However, our investigation shows
that many items are still poorly reported, so there remains much room
for improvement. To improve the clinical value of published prognosis
research in cancer authors, editors and peer reviewers should be aware
of and follow reporting recommendations.
References
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Background: Incorporating imaging modalities into clinical trials and
healthcare research presents particular challenges: What should be
measured, and how? What summary statistic should be used? How can
we best handle large amounts of multiple testing? How can reliability
and misdiagnosis be assessed, and what are their implications?
Aims: The NIHR Statistics group (http://www.statistics-group.nihr.
ac.uk/) aims to promote statistical methodology, provide educational
opportunities, share best practice and develop a community of statis-
ticians funded by NIHR research units or grants.
Activities: The NIHR Statistics group Imaging Studies Section of the
group provides a forum to address statistical issues in the design and
analysis of imaging studies. The group aims to facilitate networking
among statisticians, data analysts and other methodologists working in
this area.
The Imaging Studies Section organises meetings every six months,
with presentations on statistical challenges in imaging studies, small
group discussions to share design ideas and expertise, and network-
ing. A working group has been formed to organise meetings and
facilitate related activities.
Our first meeting took place on the 22nd October 2014 at University
of Oxford, attended by 25 members.
Subsequent meetings have been designed for and attended by 22 to
25 attendees, to provide small group networking and discussion as a
key focus on topic specific areas
 27th April 2015 at Warwick University in collaboration with
University of Oxford, focus and discussions on inter-rater
agreement and reproducibility of endpoint assessment within
the context of clinical trials in Inflammatory Bowel Disease.
 11th November 2015 at University of Birmingham in collaboration
with University of Leeds, discussing statistical issues in designing a
large-scale reliability exercise in ultrasonography of the joint
synovium.
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 20th April 2016 at University of Oxford with attendee
presentations and discussion of sample size issues in
imaging studies.
This poster will outline the key statistical issues that need to be
addressed when designing and analysing studies that use medical
imaging, and will also summarise the current and future plans of
the Imaging Studies Section.
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Background: Model-based health economic evaluations of tests have
become increasingly popular as they allow many different types of
evidence to be considered and incorporated, in addition to facilitating
estimates of cost-effectiveness beyond the duration of available study
data. To parameterize a cost-effectiveness model fully, evidence on all
the ways a test impacts on patient health must be included.
Objectives: To update an existing systematic review of the methods
used to meta-analyse diagnostic accuracy studies and evaluate how
the results have been incorporated into subsequent cost-effectiveness
analyses.
Methods: HTA reports published since May 2009 were included if they:
1) evaluated a diagnostic test, 2) included a health economic evaluation
and 3) included a systematic review of test accuracy. The following in-
formation was extracted from each report: 1) the types of evidence
searched for and identified in systematic review(s); 2) the methods
used to synthesise test accuracy data; 3) the extent to which test accur-
acy meta-analyses inform cost-effectiveness model parameters.
Results: Thirty five reports met the inclusion criteria (22 of which
reported a meta-analysis). Meta-analysis of test accuracy was not
feasible in 11 reviews, usually because of a limited number of studies
and/or high between-study heterogeneity. Evidence on test-related
outcomes (8/22) and patient outcomes (11/22) was also explicitly
searched for in the systematic reviews and reported in 12/22 and 15/22
reports respectively.
The bivariate or HSROC model was implemented for in all but two
reports. However, many had to resort to statistical models that do not
account for the correlation between sensitivity and specificity for some
secondary meta-analyses due to the small number of studies or conver-
gence issues.
Four of the meta-analyses provided all the accuracy data required for
the cost-effectiveness analysis. In fourteen reports, some of the accur-
acy parameters had to be informed by single studies, expert opinion, or
assumptions. In the remaining four reports, the meta-analysis was not
used at all to inform the cost-effectiveness analyses.
Conclusions: There has been a notable improvement in the uptake of
statistically-appropriate meta-analysis methods for synthesising evidence
on test accuracy. Prior to 2009, only 2/14 HTA reports implemented
meta-analysis methods that account for the dependent relationship be-
tween sensitivity and specificity.
Notes
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Background Spin, inflation or overinterpretation of study findings
can be used by authors to positively exaggerate the interpretation of
their findings more than the results justify.
Objectives To generate empirical evidence, classify the types, esti-
mate the frequency of distorted presentation and overinterpretation
of results in prognostic factor studies in medical oncology.
Methods We selected 17 leading oncology journals with an impact
factor of 7 or more. PubMed was searched to identify primary clinical
studies evaluating one or more prognostic factors (PFs) published in
2015. Each article was independently evaluated by 2 reviewers using
a data extraction form that was extensively pilot-tested to identify
aspects of overinterpretation. We classified them as misleading
reporting, misleading interpretation and misleading extrapolation.
Results Our search identified 10 844 articles, of which 98 met eligibility
criteria. The first author was a clinician in 61 cases and 27 studies clearly
reported involving at least one statistician. The PF was assessed pro-
spectively in 8 of 56 observational studies, and in 16 of 42 clinical trials.
A for-profit funding was identified in 31 studies and REMARK guidelines
were mentioned in 12 reports. The median number of PFs per study
was 2 (Q1-Q3, 1-5). Overall survival was used as the outcome in 77
studies. The median number of statistical analyses reported per study
with regards to the prognostic factor effect assessment was 42.5 (Q1-
Q3, 15.5–86.5). Thirty-three reports reported using two or more multi-
variable models to assess the prognostic factor effect (as defined by
the adjustment variables) and 21 did not adjust. Misleading reporting
included selective and incomplete reporting of the prognostic factor
effect (n = 26 and n = 8, respectively). In 32 studies where several PF
effects were reported, 12 inconsistently used multiple statistical tests to
assess the PF effects. The conclusions focused solely on significant
results in 80 reports, and in those where there was at least one NS re-
sult, 80% of studies focused their conclusions solely on the significant
results. Misleading interpretation included not using a multivariable
model (such as log-rank test, correlation) to assess the PF effect (n = 25
and n = 59 in full-texts and abstracts, respectively). One out of 5 conclu-
sions used linguistic spin with strong statements in both full-text and
abstract. Linguistic spin of NS results was found in 28 Results sections
in the full-text and in 18 abstract conclusions. The conclusions were
inconsistent with the study findings in one out of five articles (both in
the full-text and abstract). Discrepancies between the conclusions
presented in the full-text and in the abstract were found in 18 reports.
Clinical applicability of the prognostic factor was mentioned in 44
reports, among which the extrapolation took place in a different or an
unclear clinical setting or population in 25 conclusions.
Conclusions Our study provides insight into the level of reporting
and overinterpretation of findings that were frequently inconsistent
with the results in oncology journals with high impact factors.
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Background: When choosing between therapy options a stratified
approach requires the identification of clearly defined patient sub-
groups with a common profile of response to a specific therapy.
Glucose lowering therapy for Type 2 diabetes is an ideal candidate
for stratified medicine as there are many drug classes available with
different mechanisms of action and variable response. We examined
whether the outcome of stratified medicine research is determined
by how treatment response to a therapy is initially defined.
Methods: The study population were participants with type 2 diabetes
randomised to therapy with either thiazolidinedione (TZD) or sulfonyl-
urea (SU) in the RECORD trial, followed up over a 5 year period.
We defined treatment response as A) time for HbA1c to rise to a thresh-
old HbA1c of ≥8.5% (the definition of failure applied in the trial) using
Cox proportional hazards regression B) cumulative reduction in HbA1c
from baseline over time, estimated as cumulative area under the HbA1c
response curve using repeated measures mixed effects models.
We contrasted results using each definition when comparing response
to the 2 therapies in 4 pre-specified subgroups defined by gender and
obesity (BMI </≥30) - non-obese males (n = 468), obese males (n = 716)
non-obese females (n = 264) and obese females (n = 773). These sub-
groups had been previously identified as candidates for stratification in
analysis of routine clinical practice data (CPRD).
Results: Using definition A treatment response by therapy was similar
for non-obese males (HR TZD vs SU 1.00, 95% CI 0.72–1.40) but was
better on TZD than SU for obese males (HR 0.72, 95% CI 0.55–0.94),
non-obese females (HR 0.52, 95% CI 0.32–0.84) and obese females (HR
0.52, 95% CI 0.38–0.68).
In contrast, using definition B response by therapy was better on SU
than TZD for non-obese males (5 year HbA1c 7.1 mmol/mol lower,
p = 0.002) but similar in obese males (HbA1c 2.2 mmol/mol lower on
TZD, p = 0.30). In agreement with definition A, response was better on
TZD compared to SU in non-obese females (11.2 mmol/mol lower,
p < 0.0001) and obese females (18.8 mmol/mol lower, p < 0.0001).
Conclusion: Choice of response definition may strongly influence
results when comparing the efficacy of different therapies for stratified
medicines research. Studies seeking to identify subgroups with differ-
ential response to therapy should examine multiple definitions of re-
sponse, and consider carefully the clinical relevance of each definition.
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Background: Prediction models, both diagnostic and prognostic, are
developed with the aim to guide clinical decision making. To valid-
ate, evaluate their impact and eventually use these models in clinical
practice, clear and comprehensive reporting of prediction modelling
studies is required. To improve the reporting of prediction models, a
guideline for Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis (TRIPOD) was launched
in January 2015. The TRIPOD statement is a checklist of 22 main
items considered essential for informative reporting of studies devel-
oping or validating multivariable prediction models.
Objectives: To assess the quality of reporting of prediction modelling
studies that were published before the launch of TRIPOD in 2015.
Methods: We selected the 10 journals with the highest impact factors
within 37 clinical domains. A PubMed search was performed to identify
prediction models published in May 2014. Publications that described
the development and/or validation of a diagnostic or prognostic pre-
diction model were considered eligible. We also included studies evalu-
ating the incremental value of adding a predictor to a model. TRIPOD
items were translated into a data extraction form, which was piloted
extensively. Three reviewers extracted data. If they disagreed on when
to consider an item “adhered”, it was discussed in consensus meetings
with the other co-authors.
Results: Our search identified 4871 references, of which 347 potentially
eligible references were assessed in full text. Eventually 148 references
(within 28 clinical domains) met our eligibility criteria. Of these, 17%
described diagnostic and 83% prognostic prediction models. Model
development was described in 43% of the publications, validation of
an existing prediction model in 26%, incremental value of adding a pre-
dictor to a model in 19% and a combination of development and valid-
ation of a model was described in 12%.
The analysis showed that overall a mean of 48.4% of the TRIPOD items
(on publication level) was adhered (range 20.7%–72.4%). The mean
adherence was 46.5%, 51.4%, 47.1% and 48.5% in publications about
development, validation, incremental value and combination of devel-
opment and validation, respectively. There was incomplete reporting of
TRIPOD items concerning title and abstract, blinding, model building
procedures, final model and performance measures. Source of data,
eligibility criteria, study limitations and overall interpretation were ad-
equately reported in the majority of publications.
Conclusions: There is room for improvement in the reporting of
multivariable prediction models: more than half of the TRIPOD
items are currently not or inadequately reported. Our study could
serve as a baseline measurement for future research evaluating the
impact of the introduction of the TRIPOD statement.
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Background: Stratification of therapy based on expensive testing is
unlikely to be widely adopted in type 2 diabetes, as it is a common
disease with relatively inexpensive treatment, and lower gains in
mortality and morbidity compared with cancer. A stratified ap-
proach would need to be based on routinely available clinical cri-
teria. Big data, in the form of population datasets such as CPRD,
and industry trial data made available through Clinical Study Data
Request, provide an opportunity to explore clinical predictors of re-
sponse to treatment. Observational data has advantages of large
sample size, but may be subject to bias and confounding. Trial data
remove potential bias by randomization of therapy, but recruited
patients do not necessarily reflect the “real world” setting. These
datasets were not designed to answer questions of stratification “a
priori” so replication is essential to ensure results are not due to
chance. We aimed to use both observational and trial data to identify
clinical predictors of response to second line therapy (thiazolidine-
diones (TZD) and sulphonylureas (SU)) in Type 2 diabetes.
Methods: Associations between clinical features and glycaemic re-
sponse (1 year baseline-adjusted change in HbA1c) were assessed in
patients treated with SU (n = 8748) and TZD (n = 8876) in UK primary
care data (CPRD). Initial and longitudinal response were assessed
from 3 monthly HbA1cs over 5 years in 2 randomised controlled tri-
als of TZD v SU (ADOPT trial (TZD n = 1390; SU n = 1335) and REC-
ORD (TZD n = 1354; SU n = 1319).
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Results: In CPRD, obese (BMI > 30) female patients had 4.4 mmol/
mol better 1 year glycemic response to TZD than SU (p < 0.001),
whilst non-obese males had a 3.5 mmol/mol better response to SU
than TZD (p < 0.001). These findings were replicated in ADOPT:
obese females mean HbA1c 4.8 mmol/mol lower per year on TZD;
non-obese males 2 mmol/mol lower per year on SU. Obese males
and non-obese females both had better initial (1 year) response to
SUs (3.3 mmol/mol and 2.9 mmol/mol better on SU, respectively),
but over 5 years, obese males had greater response to TZD
(1.13 mmol/mol) and non-obese females had a similar response to
both (0.01 mmol/mol difference). Results were similar in RECORD.
Discussion: Glycaemic response to diabetes medications can be
stratified using simple clinical criteria (gender and BMI). By replicating
results in observational data and two trials we were more confident
that our findings were not due to chance, bias and confounding that
would be a concern if only carrying out analysis in one dataset. We
propose initial analysis in observational data and replication in trials
may provide a potential framework for identifying robust response
strata in common disease.
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Background: Many screening questions face the problem that, due
to low disease prevalences, studies need to have enormous sample
sizes in order to detect statistically significant effects on patient-
relevant outcomes.
Methods: We report on the results of an IQWiG benefit assessment
of neonatal pulse oximetry screening (POS) for the detection of
critical congenital heart disease (cCHD). Two different analytical strat-
egies to assess the benefits of POS were compared: The ‘classical’
intention-to-screen (ITS) analysis using all participants as denomin-
ator and the ‘alternative’ analysis using only those participants who
were affected by the disease.
Results: Only one concurrent controlled study (de Wahl-Granelli
et al., 2009) could be included in the systematic review. Based on all
155.567 newborns (ITS analysis), the study failed to show a statisti-
cally significant effect of screening on severe acidosis (OR 0.490
[0.217; 1.109], p = 0.086). Using only babies with cCHD as denomin-
ator (n = 160), the study reported a significant effect on severe acid-
osis (OR: 0.268 [0.110; 0.654], p = 0.003).
Discussion: In most screening trials, it is useful to analyze results based
on the ITS approach, because the screening interventions themselves
affect the prevalence of disease (e.g. by detecting clinically insignificant
cases). Thus, using only participants with the disease as denominator
might introduce bias into the analysis. In the context of cCHD, however,
all affected newborns are destined to die when left untreated – there-
fore bias is unlikely. Nevertheless, for comprehensive assessment of a
screening intervention, harms have to be examined within the total tar-
get population.
Conclusion: It is obvious that the benefit of screening primarily evolves
from the treatment of affected people. Therefore – if bias is unlikely –
the demonstrated benefit in diseased people may justify the imple-
mentation of the program, even if the effect on the screened popula-
tion fails to demonstrate significance. Therefore – if possible and
reasonable – when evaluating screening interventions an analysis of
results using the affected population as denominator seems to answer
a relevant question.
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Introduction: Primary studies evaluating diagnostic tests encounter
unique methodological challenges. To calculate the diagnostic accuracy
of the new test, the reference standard results are traditionally dichoto-
mised into two possible outcomes, target condition present or absent.
Therefore these outcomes are critically dependent on the definition of
disease for both the reference standard and the index test. However in
some conditions where the diagnosis is based on clinical examination a
diagnosis of disease suspect may be used. In striving to detect early dis-
ease, for example in glaucoma diagnosis where treatment cannot re-
verse existing sight loss, challenges are introduced to completing the
traditional 2 × 2 table. Glaucoma suspect is a common diagnosis
among individuals referred to hospital eye services. NICE recommends
follow-up for glaucoma suspects. The decision as to how to handle sus-
pected disease cases within the analysis is strongly influenced by the
diagnostic question being asked. The aim of this study was to explore
how suspected disease could be handled with an analysis and the im-
pact of follow-up on diagnosis.
Methods: We originally conducted a paired study of the diagnostic
accuracy of four imaging techniques for glaucoma in new referrals to
UK NHS secondary care. The reference standard was a clinical diagnos-
tic assessment by an experienced ophthalmologist masked to imaging
results. Possible diagnoses were glaucoma; no glaucoma related find-
ings; glaucoma suspect; ocular hypertension (OHT); primary angle clos-
ure (PAC); PAC suspect. Imaging tests gave a glaucoma classification
(outside normal limits, borderline, within normal limits) or were classed
as indeterminate or missing. Analyses explored the causes of indeter-
minate results, alternative diagnostic scenarios including indeterminate
results and alternative thresholds for the tests and reference standard.
A 2 year follow-up study of the glaucoma suspects was undertaken to
examine the performance of the reference standard.
Results: Nine hundred thirty-two participants were included in the
analysis of ‘worse eye’ diagnosis. Glaucoma was diagnosed in 17% of
cases and no glaucoma in 32.1%. A further 26% were classified as
‘glaucoma suspect’. The remaining cases were OHT (12.3%), PAC (3.3%),
PAC suspect (8.9%). In 4 cases the reference standard measurement
was indeterminate (0.4%). Between 4 and 8% of imaging outputs were
classed as indeterminate and this varied amongst imaging techniques.
Indeterminate imaging results were further classified into low quality
result; no automated classification generated; imaging artefact; patient
unable to undertake test. After monitoring in secondary care the classi-
fication of glaucoma suspects was changed.
Conclusions: In diagnosing disease, a true diagnosis at a single point in
time may not be possible and high proportion of ‘suspect’ cases may
be identified who may later be confirmed as disease or no disease. Al-
though analyses can treat the suspect cases as with or without disease,
the true incidence of disease may only be determined after a period of
monitoring and assessment and this may inform the optimum timing
for the reference standard measurement for test accuracy studies. In
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considering study design, the likely proportion of ‘suspect’ cases and
methods to follow-up ‘suspect’ cases should be considered.
Funding: NIHR HTA Programme 09/22/111 and International Glaucoma
Association.
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Economic Evaluations can support the adoption of an intervention into
the NHS. The majority of these evaluations are carried out on fully de-
veloped interventions. In the case of diagnostic tests, early evaluation
(during test development) is necessary to ensure the test addresses a
need; can feasibly address the identified need; and is cost effective. To
enable a robust early evaluation, we have combined Human Factor
(HF) - also known as Ergonomic - methods with qualitative methods to
better inform the evaluation of such diagnostics.
HF is a discipline that applies various tools, theories and principles to
inform the design of aspects of a system so that human interaction
with this system may be optimized. We have found that combining
these methods is necessary due to the indirect way in which diag-
nostic tests affect health outcomes. To understand and evaluate
diagnostic and their relevant treatment strategies, clinical pathways
must be mapped by stakeholders of the diagnostic information pro-
duced by the test. Identifying and prioritizing stakeholders may be
done using a commonly used HF tool- Stakeholder Identification Tool
(SIT) which enables a stakeholder’s interests and needs (as well as
influence over NHS adoption) to be informed by responders.
Unlike other industries whose stakeholders are identified by the
intervention’s manufacturer, diagnostic tests must be informed by
those who understand the test output utility within NHS pathways.
We have utilized SIT in the mapping of clinical pathways by enabling
responders to identify the test role for each stakeholder type. This
has better informed the selection of stakeholders to inform the map-
ping of clinical pathways which will be the basis of the test’s
economic evaluation.
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Clinical pathway mapping (CPM) has many uses in healthcare. For
example, it is fundamental to the assessment of healthcare interven-
tions. CPM is a heuristic technique, which by definition aims to
simplify the real world. We present the limitations associated with
four methods of CPM that predominantly relate to the content and
construct validity of care pathway models:
a. Staff interviews using champions
b. Staff interviews using a Delphi method
c. Starting with an NHS guidance document
d. Using grounded theory approach with multiple experts
Economic evaluations of medical technologies, particularly those that
have not been tested in clinical trials, are reliant on the development
of accurate models; reliable forecasts of potential clinical and eco-
nomic benefits are predicated on these. We aim to demonstrate
which CPM method(s) is/are most appropriate for different types of
research: diagnostic evaluation and health policy.
Economic evaluations require context-relevant conceptualizations
of processes which allow for accurate modelling and forecasting.
This immediately points to the need for CPM to be informed by
stakeholders within the pathway(s) of the intervention that needs
to be evaluated. As practice varies across the NHS, how possible is
it to capture such processes (with reduced bias) using NHS
stakeholders?
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Focus within the “Start Smart, Then Focus” national guidance aims to
ensure prescribed antibiotics in secondary care settings are reviewed
within 72 hours of initiation leading to appropriate prescribing deci-
sions. Decisions include stopping, continuing, changing from IV to oral
or changing to a completely different set of antimicrobials. To enable
these decisions to be made, clinicians are often left with no further in-
formation other than the often empirical information used to initiate
antimicrobials. Recent technological advances such as multiplex PCR
have quickened the time to results in these environments leading to
quicker identification of the causative organism and the antimicrobial(s)
that it is susceptible to.
To understand the continued problems of antimicrobial review within
secondary care settings which utilize such advanced technology, we
carried out a service evaluation in admission wards across Imperial
College Healthcare NHS Trust. The data collected was supported by
short interviews (using a semi-structured questionnaire) with clinicians
who had reviewed the antibiotic prescription of identified patients. All
patients on adult admission wards who were initiated on antibiotics
during their current admission were included in the service evaluation.
Data was collected over one week in the admission wards of each of
the three hospitals in the Trust in October/November 2015.
A purposeful sampling method was used to recruit clinicians for inter-
view – clinicians involved in antibiotic review were identified and
approached for interview. We aimed to identify the events which in-
formed changes to initiated antibiotics during the service evaluation.
Interviews aimed to collect the opinion of clinicians in two ways: i) what
informed changes in the patient they were identified as having
reviewed the prescription of and ii) what informed changes at different
stages of antibiotic prescribing. We also sought to understand their
thoughts on point of care tests (POCT) and how they felt POCT could
improve antibiotic review.
The antibiotic prescriptions of a total of 106 patients were
observed. The most frequent themes explained the reasoning
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behind decisions made and included the improvement of a pa-
tient’s clinical state; awaiting diagnostic information; obtaining
antibiotic information; changes in diagnosis or indication; and be-
ing informed by guidelines or other diagnostic information. Using
this thematic framework, we aim to scan the horizon for current
and emerging diagnostics that can improve antibiotic review and
evaluate the likelihood of adding value to the real issues sur-
rounding antibiotic review within secondary care.
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Calculating the cost effectiveness of an intervention during an
economic evaluation utilizes health outcome as well as cost in-
formation. Such information is usually sufficient when informing
decision makers and budget holders of the added value that the
intervention brings to specific clinical pathways. In the area of
diagnostics, it is increasingly clear that diagnostic tests need to
be evaluated earlier in their development process i.e. early eco-
nomic evaluations. This is to ensure that the diagnostic’s route
to development is appropriate and informs the current needs of
the environment it aims to bring added value to.
In the early development of diagnostic tests, Human Factor ana-
lysis – also known as Ergonomics – informs manufacturers of the
feasibility and usability of their test by stakeholders who will
utilize said test within clinical pathways. Using such output, it is
possible to establish the likelihood of use by stakeholders along
a diagnostic and treatment pathway.
Incorporating this information into economic evaluations ensures
that decision makers are more informed of the likely added value of
a test by not assuming 100% uptake.
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Background: The early introduction of biomarkers, before identifying
existing gaps in clinical care and defining how the biomarker re-
sponds to unmet needs and is intended to be used to improve care,
can lead to inappropriate utilization of tests and resources.
Objective: We aimed to define a strategy and a checklist for identifying
unmet needs for new medical tests.
Design: A multidisciplinary working group of laboratorians, EBM,
HTA, policy experts, and the IVD industry used a 4-step process: 1/
scoping literature review; 2/ eight face-to-face meetings to discuss
the scope, strategy and checklist items; 3/ iterative process of feed-
back and consensus to develop the checklist; 4/ testing and refine-
ment of checklist items by using case scenarios.
Results: Using a clinical pathway mapping approach to identify the
clinical management decision linking biomarker testing to health out-
comes, we developed a 14-item checklist organized in 4 domains: 1/
identify and 2/ verify the unmet clinical need; 3/ validate the intended
use; and 4/ assess the feasibility of the biomarker. We present an
outcome-focused approach that can be used by multiple stakeholders
for any diagnostic test, irrespective of the purpose and role of testing.
Conclusions: The checklist intends to achieve more efficient biomarker
translation and facilitate multidisciplinary collaboration by early critical as-
sessment of the clinical pathway and potential impact of new biomarkers
on health care outcomes. We propose that the checklist is field tested and
validated by various stakeholder groups, and advocate the role of the la-
boratory professional to foster trans-sector collaboration in this regard.
Reference
1. Horvath, A. R., S. J. Lord, et al. (2014). “From biomarkers to medical tests:
the changing landscape of test evaluation.” Clin Chim Acta 427: 49–57.
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Introduction: Overdiagnosis is increasingly discussed in scientific lit-
erature over the last decades (see Fig. 10). Consequences of overdi-
agnosis involve unnecessary expenditure of healthcare budget as
well as an increased risk of side-effects or complications related to
testing or subsequent treatments. In this systematic review we pro-
vide an overview of articles on the subject of overdiagnosis to gain
insight into the diversity of methodological challenges faced.
Methods: Pubmed was searched using text words and MeSH terms re-
lated to overdiagnosis, overdetection and insignificant disease. Titles
and abstracts of these papers were screened by two independent re-
viewers assessing which clinical domain they entailed, type of index test,
type of paper (e.g. primary study, review), suggested solutions to tackle
overdiagnosis and whether overdiagnosis was a dominant theme.
Results: Three thousand eight hundred two papers were identified.
The following results are based on the 2158 most recently published
papers. After exclusion of non-English papers and papers without
full-text available, the titles and abstracts of 1831 papers were
screened. Articles in which overdiagnosis was a dominant theme
were selected, yielding 956 papers for further analysis.
There were 19,2% methodological papers related to overdiagnosis.
Overdiagnosis is subject of discussion in various contexts spread
across different medical disciplines. The clinical domains in which it
is mostly discussed are oncology, mental disorders and infectious dis-
ease, with 60,0%, 8,2% and 5,2% respectively. The test most com-
monly evaluated is imaging. Overdiagnosis is most often addressed
in the context of diagnostic accuracy, however also in terms of dis-
ease communication, disease definition and as a broad general topic.
Discussion / conclusion: A growing number of papers discuss overdiag-
nosis, using many different definitions. It is addressed predominantly in
breast, prostate and thyroid cancer screening, however papers on the
subject can be found over virtually all clinical domains. This overview
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can serve as a starting point for further methodological advancements
in the field of overdiagnosis.
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Background: Policy making bodies like NICE use a “linked evidence” ap-
proach where the amount of diagnostic misclassification evidenced by
accuracy studies is linked using a decision-analytic or other appropriate
modelling approach to the consequences of this misclassification pro-
vided by evidence on effectiveness of downstream treatments.The link-
age approach could be extended to primary evaluation. In this different
aspects of the impact of tests not feasibly measured in a single RCT are
evaluated in separate clinical studies or using observational data, and
then linked via a model. We suggest the term composite test evaluation
to describe a programme of studies designed with the intent of feeding
into a model which integrates the results to provide an estimate of over-
all effectiveness or cost-effectiveness. A preliminary version of the model
may help identify aspects of impact where there is greatest uncertainty
as targets for the primary studies.
Objectives: To reflect on two completed projects where we have
employed composite test evaluation.
Methods: The first project concerned the effectiveness and cost-
effectiveness of strategies to maximise identification of single gene dia-
betes (MODY), an example of stratified medicine, and the second the ef-
fectiveness and cost-effectiveness of school entry hearing screening. In a
case study approach the investigators involved in developing the plans
for these studies reflected on the strengths and weaknesses of compos-
ite evaluation, particularly challenges encountered in both projects.
Main results: Both projects provided evidence on effectiveness and
cost-effectiveness in a time that was less than might be taken for an
RCT, if indeed an RCT was feasible in either case. We identified many
challenges, but would particularly highlight:
 Complexity of the approach
 Clearly establishing the areas of greatest uncertainty at the
design stage
 Tendency to over-elaborate the model
 Justifying use of new data from clinical studies over any existing
data
 Difficulty of publishing all clinical studies, resulting in loss of
transparency
 Challenge of identifying this approach as being distinct from
standard economic modelling
Authors’ conclusions: Composite evaluation of tests is a useful
additional evaluative approach but is not a panacea and requires
resource and time to do well.
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Background: Probabilistic decision modelling has become an important
part of economic evaluations of health technologies, however informing
the parameters of such models is sometimes challenging, because of insuf-
ficient data. One way to deal with a lack of data is to derive distributions
from expert judgements, an approach referred to as expert elicitation.
In this study, we set out to explore the feasibility of using expert
elicitation to characterise the time resource in implementing two
screening tests for hearing impairment at school entry: (1) pure tone
sweep audiometry (PTS) and (2) the Siemens HearCheck device (HC).
Methodology: Health professionals with experience in hearing impairment
screening were invited to participate in the study. Experts agreeing to
participate were emailed an Excel-based elicitation tool containing a training
element as well as recording the opinions of the experts about the two
hearing tests. Experts were also invited to comment on the format of the
questions and ease of use of the tool.
Results: Seven experts provided their procedure time estimates for the two
hearing tests. Five responses were obtained within the first four weeks of
the study, while all seven responses were available after six weeks. There
was good agreement among the experts regarding the duration of the two
procedures. Overall, experts estimated the time taken using HC to be shorter
(mean 4 minutes) than time taken using PTS (mean 7.8 minutes). None of
the experts reported any difficulties in completing the questionnaire.
Conclusions: Expert elicitation is feasible within the context of an
economic evaluation and can be conducted in a reasonable time. For
the quantity of interest in this study, conducting the elicitation in the
absence of a facilitator raised no issues.
P56
Revisiting the place of diagnostic case-control studies prompted
by issues raised by a comparative accuracy study of two methods
of hearing screening
Chris Hyde1, Obi Ukoumunne2, Jaime Peters1, Zhivko Zhelev1
1Exeter Test Group, University of Exeter Medical School, Exeter, UK;
2Statistics Group, NIHR CLAHRC South West Peninsula (PenCLAHRC),
University of Exeter Medical School, Exeter, UK
Correspondence: Chris Hyde (c.j.hyde@exeter.ac.uk)
Diagnostic and Prognostic Research 2016, 1(Suppl 1):P56
Background
In diagnostic case-control, or two-gate accuracy study designs partici-
pants are drawn separately from two distinct populations. “Cases”
with confirmed disease are used to estimate sensitivity, and “con-
trols” without identifiable disease, are used to estimate specificity,
predictive values not being directly estimable. With the exception of
the very initial evaluation of test accuracy, diagnostic case-control
studies are not recommended as a main stream primary test evalu-
ation design as awareness has grown about the threat to validity
posed by spectrum bias. Because of very low disease prevalence, we
were compelled to adopt such a design, in a recent research
programme on the evaluation of school entry hearing screening.
Objectives
To consider the advantages and disadvantages of a diagnostic case-
control study we conducted, reconsidering the alternative study
designs available to us.
Methods
We reflected on the results of the study particularly assessing the
degree to which openness to bias negated our findings. The perspec-
tives of two members of the team who were involved in developing
the original protocol were balanced against the views of two
researchers who had not been involved.
Main results
The study results were a sensitivity of 94.2% (95% CI 89.0, 97.0) for test
A, and 89.0% (95% CI 82.9 to 93.1) for test B (p < 0.02). For specificity
they were 82.2% (95% CI 77.7, 86.0) for test A and 86.5% (95% CI 82.5
Fig. 10 (abstract P51). See text for description
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to 90.0) for test B (p < 0.02). It is unclear whether alternative study
designs to the case-control study design chosen would have been feas-
ible. Further we identified that the bias associated with case-control
studies had less impact on our main objective to compare tests, than if
we had simply been interested in the values of accuracy of a single test.
Nevertheless caution still needs to be exercised quantifying the differ-
ence in accuracy between the two tests. We were also able to clearly
demonstrate important differences in the accuracy between cases
identified by different methods directly demonstrating the important
influence of population and setting on accuracy.
Authors’ conclusions
We think we have identified some reasons why diagnostic case-control
studies should be retained as an option for mainstream study design
for accuracy. The rehabilitation of this study design should include
rediscovering skills in conducting diagnostic case-control studies so
that if they are conducted, this is done in a way which minimises the
bias to which they are clearly susceptible.
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Background: Selective outcome reporting in clinical trials is well
understood, but has not been assessed systematically in studies of
diagnostic test accuracy, where authors often report results for a
small range of ordinal cutoffs around data-driven “optimal” cutoffs
maximizing sensitivity and specificity.
Objectives: To compare traditional meta-analysis of published results
to individual patient data (IPD) meta-analysis of results from all
cutoffs, to: (1) assess the degree to which selective cutoff reporting
exaggerates accuracy estimates, and (2) identify patterns of selective
cutoff reporting.
Methods: Bivariate random-effects models were used to compare
results of traditional and IPD meta-analysis, using studies included in
a published meta-analysis of the Patient Health Questionnaire-9
(PHQ-9) depression-screening tool (Manea et al., CMAJ, 2012).
Results: 13 of 16 primary datasets were obtained. For the “standard”
cutoff of 10, most studies (11 of 13) published accuracy results. For all
other cutoffs, only 3–6 of the 13 studies published accuracy results. For
all cutoffs, specificity estimates in traditional and IPD meta-analyses
were within 2%. Sensitivity estimates were similar for cutoff 10, but dif-
fered by 5–15% for all other cutoffs. In samples where the PHQ-9 was
poorly sensitive, authors reported results for cutoffs around the low op-
timal cutoff. In samples where the PHQ-9 was highly sensitive, authors
reported results for cutoffs around the high optimal cutoff. Conse-
quently, in the traditional meta-analysis (but not in the IPD meta-
analysis), sensitivity increased as cutoff severity increased for part of
the range of possible cutoffs. Comparing cutoff 10 across all studies,
sensitivity was heterogeneous (tau-squared = 1.95). Comparing optimal
cutoffs, however, sensitivity was more homogeneous (tau-squared =
0.68), but optimal cutoff values ranged from 5–15.
Conclusion: Selectively reporting well-performing cutoffs in small
samples leads to biased estimation of accuracy in traditional meta-
analyses. To reduce bias in meta-analyses, primary studies should re-
port accuracy results for all relevant cutoffs.
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Background: The use and evaluation of pharmacogenetic tests is rap-
idly increasing, and decision models are often employed to conduct
economic evaluations of these tests. These models must reflect clin-
ical pathways for both testing and treatment, hence a great deal of
evidence is often required. In parameterising these models, attention
is commonly focused on treatment effectiveness and test accuracy,
with systematic reviews often informing the identification of these
model parameters. However, these parameters may not be the main
drivers of decision models: evidence on test-related factors such as
uptake, test repeats or failures and consequences of false test results
may be just as, or more, important.
Aim: To understand what evidence is being included in decision
models constructed to inform economic evaluations of pharmacoge-
netic tests, to describe how test-related evidence is identified and
reported, and to evaluate the quality of this evidence.
Methods: We have undertaken a systematic search of the literature
to identify published articles reporting the use of decision models to
conduct economic evaluations of pharmacogenetics tests. Decision
models were not restricted by type of economic evaluation, therefore
cost-effectiveness, cost-utility, cost-benefit, cost-minimisation and
cost-consequence analyses were all included. Information on the
decision problem, the structure and perspective of the analysis, and
the evidence used in the model will be extracted from each article,
along with details of the use of sensitivity analyses to explore varia-
tions in test-related parameters. The quality of the decision models
will also be appraised, and the use of good practice or reporting
guidelines will be noted.
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Results: Analysis is on-going, but pilot work suggests that reporting
on aspects of pharmacogenetic testing in the models is poor. More-
over, details on how test-related evidence are identified, or whether
there has been any form of quality appraisal are lacking. We will
report on the full analysis of these articles.
Conclusions: This is the first review of decision models for pharmaco-
genetic tests to focus on the test-related evidence used in the deci-
sion models, specifically the source and quality of evidence used.
Early analyses indicate that few studies provide sufficient detail on
how evidence was identified for use in the model, nor is the quality
of this evidence evaluated. Although sensitivity analyses are under-
taken to assess the impact of test-related evidence, clarity on the
importance and quality of test-related evidence is needed in
published decision models.
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Introduction Chronic reflux of acid into the gullet from the stomach
causes irritation to the lining of the gullet. In the presence of this irri-
tation, the lining undergoes a change called Barrett’s Oesophagus
(BO). This is a pre-cancerous condition which requires close monitor-
ing to detect cancer of the oesophagus (gullet) in its early stages. If
detected early, the cancer is easier to treat and survival is greatly
improved. While less than 1 in 100 people with BO will go on to
develop cancer, the incidence of oesophageal adenocarcinoma
(OADC) is increasing. There is currently no robust method to identify
those with BO at a high risk of developing OADC, other than regular
screening using endoscopy and biopsy to ensure there is no progres-
sion. This places a large burden on screening endoscopy services
and subjects patients to regular invasive endoscopic screening which
may not be of benefit as a large proportion of patients will never
progress to OADC.
Previous studies have shown that methylation and other epigenetic
biomarkers may play a role in the identification of high risk patients
with BO.
Aim Our aim is to develop a panel of epigenetic biomarkers to strat-
ify patients with BO in terms of their risk of developing cellular atypia
and subsequent OADC. The choice of biomarkers will be informed by
a systematic review of existing evidence on the utility of epigenetic
markers to predict progression.
Method Standard systematic review methods aimed at minimising
bias will be used. Prospective and retrospective studies will be eli-
gible if they report the association of one or more epigenetic
markers with progression from BO to OADC in adults. Data obtained
from the systematic review will be used where possible to generate
a panel of promising epigenetic biomarkers. A laboratory validation
of these biomarkers will then be conducted. Archival tissue samples
from BO patients who have and have not progressed to OADC which
will be compared using whole genome methylation arrays and next
generation sequencing techniques to assess potential prognostic
value of the biomarker panel. If validated successfully a prospective
clinical trial using fresh tissue samples obtained from endoscopic
biopsies will be designed.
Results Searches for the systematic review have been performed,
and records are currently being screened for eligibility. Synthesis of
results is expected to be completed by the end of June 2016, and
the choice of panel finalised with laboratory validation beginning in
July 2016. It is anticipated that the findings from both the systematic
review and the subsequent validation study will ultimately be useful
in guiding risk stratification in BO patients. This could lead to a
change in current clinical practice by potentially reducing the num-
ber of invasive screening endoscopies for patients who are at lower
risk of progression to OADC whilst increasing the frequency of
screening for those at high risk, facilitating diagnosis of OADC at an
earlier stage which can in some cases be treated with endoscopic
mucosal resection rather than oesophagectomy, a procedure associ-
ated with much greater morbidity. Treating OADC at an earlier
disease stage greatly improves 5 year survival rates.
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Background: Development of diagnostic guidelines may rely on the
conclusions of existing diagnostic test accuracy systematic reviews
(DTA reviews) for pragmatic reasons. In addition justification for
undertaking a new DTA review should be based on an assessment of
the quality (methodology of the review process and clinical applic-
ability) of the existing evidence base. However, currently there is no
specific tool for assessing the quality of DTA reviews.
The process of undertaking a Cochrane DTA review (Symptoms,
ultrasound imaging and biochemical markers alone or in combin-
ation for the diagnosis of ovarian cancer in women with symptoms
suspicious of ovarian cancer) provided the opportunity to assess the
quality of a considerable existing DTA review evidence base using a
quality assessment tool devised by the authors.
Objectives: 1) Assess the usability of a new quality assessment tool
for DTA reviews. 2) Present suggested refinements to the tool follow-
ing this initial pilot, for discussion.
Methods: Electronic databases, including Medline, Embase and
Cochrane, were searched from 1991 to December 2014 for system-
atic reviews assessing the diagnostic test performance of symptoms,
FDA approved biomarkers, ultrasound and test combinations in non-
pregnant women ≥18 years suspected of ovarian cancer. Data extrac-
tion was performed in duplicate and included clinical information
that may impact on test accuracy estimates (population and index
test characteristics) and review quality. A quality assessment tool was
derived by the authors drawing on the AMSTAR and STARD reporting
standards, QUADAS-2 and current guidelines for the conduct of
Cochrane DTA reviews. The tool currently comprises 3 domains, within
which quality judgements are made for a number of components on:
1)Methods: components include question formulation, search strategy,
data extraction, quality assessment, statistical methods.2)Results: com-
ponents include study flow, participant characteristics, index test charac-
teristics, quality of included studies, test accuracy estimates.3)Discussion:
components include review method limitations, limitations of included
studies, clinical applicability.
Results and vonclusions: A total of 21 reviews have been included
for appraisal after titles and full text screening.
Included reviews span the period from 1966 to October 2013 spear-
headed from the USA, Europe and China. The reviews provide diversity
in terms of index tests (symptoms, several biomarkers, different ultra-
sound technologies and test combinations) and included primary
studies (include case control studies and retrospective and pro-
spective studies).
The authors’ experience of using the new DTA quality assessment
tool will be presented including time demands, agreement between
assessors and the process of moving from documentation of review
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methods and making an overall assessment of quality in each of the
3 domains. Suggested refinements to the tool will be presented for
discussion.
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Background: Assessment of treatment response in routine clinical
practice in castrate resistant prostate cancer (CRPC) is a major chal-
lenge. In patients with bone only disease, response evaluation criteria
in solid tumours (RECIST) are not usually useful and whilst consensus
criteria based on PSA, clinical and radiological biomarkers are avail-
able they are used inconsistently. Most clinicians rely on clinical
symptoms to drive treatment switch decisions suggesting the need
for more precise biomarkers. Shedding of tumour cells into the circu-
lation is a necessary step for the formation of metastases. Multiple
assays and devices are available to detect, isolate, enumerate and
characterise circulating tumour cells (CTC) and having demonstrated
analytical validity and clinical validity in clinical trials, the CELL-
SEARCH®(Janssen Diagnostics, LLC) system has regulatory clearance
as an aid in monitoring patients, with metastatic breast, colorectal
and castrate resistant prostate (CRPC) cancers. In metastatic CRPC,
CTC count is prognostic for survival and CTC count decreases have
met the statistical requirements for surrogacy of overall survival.
Objective: To determine if the use of serial CTC counts can direct
early discontinuation of 1st line chemotherapy in patients with meta-
static CRPC without adversely impacting overall survival, when com-
pared with standard approaches to guide treatment switch decisions.
Methods: CTC-STOP is a multicentre phase III trial in which metastatic
CRPC patients with CTC count ≥5 cells/7.5 mL are randomised 1:1 to ei-
ther standard of care (control) or CTC guided treatment (intervention).
Serial blood samples for central CTC enumeration are taken during
treatment. In the intervention group, if a patient has two successive
CTC determinations showing progression by CTCs (defined as either (1)
failure to achieve both a 30% decline from baseline and a conversion
from “unfavourable” (≥5 cells/7.5 mL) to “favourable” (<5 cells/7.5 mL)
or, after a CTC response, either (2) conversion from favourable to un-
favourable CTC count or (3) a 30% increase in CTCs from nadir and an
unfavourable CTC count), the treating clinician will receive a recom-
mendation from the trial Chief Investigator to discontinue 1st line
chemotherapy and commence 2nd line chemotherapy at the following
cycle of treatment. All patients will complete at least 3 cycles of stand-
ard 1st line chemotherapy before any CTC-guided treatment recom-
mendation is made. In the control group, clinicians will not be made
aware of CTC count results. The trial has a non-inferiority design and is
powered to exclude a 20% increase in mortality (i.e. hazard ratio not
worse than 1.20) in patients whose treatment management has been
based on CTC values. Target sample size is 1178 patients. A feasibility
analysis after accrual of 200 patients will evaluate recruitment rates and
adherence to CTC-guided treatment recommendations. The trial will
open to recruitment in Q2 2016.
Impact: Earlier decision-making based on circulating biomarkers
could minimise morbidity and cost without adversely impacting
outcome. This may result in decreased toxicity, reduced health care
economic costs and may enable a higher proportion of patients to
receive further lines of active treatment.
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